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PREFACE 
The purpose of this dissertation is to introduce and to demonstrate a new approach 
to supporting the follow-up care of living kidney donors. This new methodology, an 
exploratory process utilizing the tools of clinical informatics applied in a statewide health 
information exchange, can be used to identify, capture, and to then assess health 
outcomes of living kidney donors in the 24-month or two-year follow-up period currently 
that is required by United Network for Organ Sharing policy.  
This dissertation should be of interest to high-level decision makers, in the 
Scientific Registry of Transplant Recipients and the Organ Procurement and 
Transplantation network specifically, but also in other large private and public 
organizations. It should also be of interest to scholars of applied clinical informatics, 
transplant administration, and surgery departments with living donor kidney transplant 
programs.  
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Macey L. Henderson 
 
LIVING KIDNEY DONOR FOLLOW-UP IN A STATEWIDE HEALTH 
INFORMATION EXCHANGE: HEALTH SERVICES UTILIZATION, HEALTH 
OUTCOMES AND POLICY IMPLICATIONS 
  
Living donors have contributed about 6,000 kidneys per year in the past 10 years, 
but more than 100,000 individuals are still waiting for a kidney transplant.  Living kidney 
donors undergo a major surgical procedure without direct medical benefit to themselves, 
but comprehensive follow-up information on living donors’ health is unfortunately 
limited. Expert recommendations suggest capturing clinical information beyond 
traditional sources to improve surveillance of co-morbid conditions from living kidney 
donors.  Currently the United Network for Organ Sharing is responsible for collecting 
and reporting follow-up data for all living donors from U.S. transplant centers.  Under 
policy implemented in February of 2013, transplant centers must submit follow-up date 
for two years after donation, but current processes often yield to incomplete and untimely 
reporting.  This dissertation uses a statewide Health Information Exchange as a new 
clinical data source to 1) retrospectively identify a cohort of living kidney donors, 2) 
understand their follow-up care patterns, and 3) observe selected clinical outcomes 
including hypertension, diabetes and post-donation renal function. 
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CHAPTER ONE: INTRODUCTION 
Overview and History of the Current U.S. System of Organ Donation 
The first successful kidney transplant took place in 1954 between twin brothers, 
paving the way for the development of the U.S. system for organ donation, recovery, 
allocation, and transplantation (Merrill, Murray, Harrison, & Guild, 1956). Since then, 
the growth and development of the field of transplantation including its structure have 
been guided by state and federal laws and regulations, making the organ transplant 
system one of the most complexly regulated areas of healthcare.   
The Organ Procurement and Transplantation Network 
The Organ Procurement and Transplantation Network (OPTN) was created by the 
enactment of the National Organ Transplant Act ("National Organ Transplant Act," 
1984). The OPTN is charged with developing policies for and implementing an equitable 
system of organ allocation, maintaining the waiting list of potential organ recipients and 
collecting and compiling data from all transplant centers in the U.S. All of the 58 
federally designated organ procurement organizations (OPOs) serving geographically 
defined donor service areas and transplant centers are required to participate in the 
OPTN.  
The United Network for Organ Sharing 
The United Network for Organ Sharing (UNOS) is a non-profit, private and 
voluntary organization that has been the sole administrator of the OPTN since the initial 
contract was awarded in 1986.  In other words, UNOS is the substantive body of the 
OPTN. The Division of Transplantation in the Health Resources and Services 
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Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) is 
the governmental agency responsible for the oversight of the OPTN contract.   
Laws, Regulation and Legislation in Organ Transplantation 
There are four main types of regulations in organ transplantation, including state 
laws, federal laws, federal regulations and United Network for Organ Sharing policies.  
The relevant legislation for organ donation and transplantation is listed in Table 1.1. In 
general, laws at the state level cover issues relating to the donation process including 
authorization, scope of public education programs, composition of deceased donor 
registries, and criteria for the determination of death.   
Federal laws on organ transplantation are primarily found in Title 42 of the 
United States Code ‘The Public Health and Welfare.’ Federal law relating to organ 
transplantation has a broad approach, primarily outlining the process of organ 
procurement and allocation by the OPTN. Of prime importance in Title 42 U.S.C. is 
Section 274a, which establishes the Scientific Registry of Transplant Recipients (SRTR). 
In addition, 42 U.S.C. Sec. 274e sets limitations and boundaries on the transfer of organs 
from one person to another, including the prohibition on buying and selling organs.  
Also important within federal law (42 U.S.C. 217a; Section 222 of the Public 
Health Service Act, as amended 42 CFR 121.12) is the establishment of the Advisory 
Committee on Organ Transplantation (ACOT). This advisory committee was established 
to assist the HHS Secretary in enhancing organ donation, ensuring that the system of 
organ transplantation is grounded in the best available medical science, assuring the 
public that the system is as effective and equitable as possible, and increasing public 
confidence in the integrity and effectiveness of the transplantation system. HRSA’s 
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Healthcare Systems Bureau provides ACOT’s management and administrative support 
services and records are to be made available for public inspection and copying 
("Freedom of Information Act," 1967). In contrast, federal legislation expands federal 
law and provides provisions for how transplant centers; OPOs and the OPTN should 
function. Federal regulations explain internal structures of organizations and their 
primary operations.   
UNOS rules are policies that every transplant center and OPO must follow in 
order to be a member of the OPTN. UNOS policies are developed through an 
administrative process that is transparent with the public. Specific committees, comprised 
of members appointed and approved by the president of the OPTN, develop policy 
proposals and disseminate them justifying their need. Next, the UNOS committee asks 
for public comments on policy proposals, where all interested parties are encouraged to 
submit responses to the proposed policy. After the public comment period concludes, the 
UNOS committee responds to public comments and submits a final proposal to the Board 
of Directors for their vote. Should the Board of Directors approve the proposal, the policy 
then becomes UNOS/OPTN rule. Policies approved by the Board of Directors with or 
without amendments are be implemented according to the OPTN Bylaws Article XI.  
Policies approved by the Board of Directors and recommended to be enforced as 
mandatory policies are forwarded for the Secretary of HHS for review and comment 60 
days before implementation (OPTN Final Rule, section 121.4(b) (2)).  
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Table 1.1- History of Legislation in the U.S. Organ Transplant System 
1968 Uniform Anatomical Gift Act (UAGA) 
 
*Model state law 
 
Provided a uniform legal environment for organ 
donation; adopted by all 50 states and D.C.; gives 
all adults the right to donate their bodies or organs 
for use upon their death “without subsequent veto” 
by others 
1981 Uniform Determination of Death Act 
(UDAA) 
 
*Model state law 
Codified and extended existing common law basis 
for the determination of death 
 
States that, “An individual who has sustained 
either irreversible cessation of circulatory and 
respiratory functions, or irreversible cessation of 
all functions of the entire brain, including the brain 
stem, is ‘dead’ 
1984 National Organ Transplant Act 
(NOTA) 
Public Law 98-507 
Established the Organ Procurement and 
Transplantation Network (OPTN) to be run by a 
non-profit entity → United Network for Organ 
Sharing (UNOS). 
Provided grants to expand regional organ 
procurement organizations, prohibited commercial 
transactions in organs, and established a Task 
Force on Organ Transplantation 
1986 Omnibus Budget Reconciliation Act 
(OBRA) Public Law 100-203 
Required that hospitals participating in Centers for 
Medicare and Medicaid Services 
(Medicare/Medicaid) implement a ‘required 
request’ policy mandating education about organ 
donation upon eligible deaths 
 
1987 Amended UAGA Enacted in 25 jurisdictions; explicitly provides 
first person-consent honoring donor autonomy,  
prohibited sale of body organs, and included 
required request provisions 
2004 Organ Donation and Recovery and 
Improvement Act (ODRIA) 
Public Law 108-216 
Authorized provision of grants for reimbursement 
for travel, food and other expenses incurred by 
living donors; established a public education 
program aimed at increasing awareness for organ 
donation; authorized grants for study, 
demonstration projects and outreach activities 
designed to increase rates of organ donation 
2007 Charlie W. Norwood Living Organ 
Donation Act 
Public Law 110-144 
Amended NOTA to reflect incompatible paired 
kidney exchange in transplantation as a practice 
that *does not* constitute ‘valuable consideration’ 
2013 HIV Organ Policy Equity (HOPE) Act 
Public Law 113-51 
Modifies rules regarding organ donation between 
HIV-positive individuals; requires OPTN to adopt 
new standards (including quality) and testing with 
respect to organs infected with human 
immunodeficiency virus; directs Secretary of 
Health and Human Services to publish research 
guidelines with respect to transplantation of HIV-
infected donors and to annually review this 
scientific research; amends the federal criminal 
code against HIV-positive individuals who give 
organs 
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Kidney Disease and Transplantation in the United States 
Kidney disease statistics for the United States convey the burden of chronic 
kidney disease (CKD) and end-stage renal disease (ESRD) for which kidney 
transplantation is the preferred treatment (Coresh, Astor, Greene, Eknoyan, & Levey, 
2003; Coresh et al., 2007; A. S. Levey & Coresh, 2012; A. S. Levey et al., 2003). The 
Centers for Disease Control and Prevention (CDC) estimate one in ten American adults, 
more than 20 million, have some level of CKD. Data from the U.S. Renal Data Service 
(USRDS) showed at the end of 2009, more than 871,000 people were being treated for 
ESRD in the U.S. Historically, between 1980 and 2009, the prevalence rate for ESRD 
increased nearly 600%, from 290 to 1,738 cases per million. According to the National 
Institute of Diabetes and Digestive and Kidney Diseases, diabetes and high blood 
pressure (hypertension) are the most common causes of kidney failure, but other factors 
include heart and blood vessel disease, and a family history of kidney failure. African-
Americans, Hispanics/Latinos, and American Indians are more likely to have kidney 
failure (USRDS, 2010). Since 1972, Medicare has covered Americans with CKD and 
transplantation as a treatment for ESRD through the End Stage Renal Disease Program 
(Public Law 92-603).   
Over 100,000 patients on the national wait list need a kidney transplant and the 
number of patients awaiting kidney transplantation in the United States has steadily 
increased over time. The gap between organ supply and demand continues to widen 
despite initiatives to expand use of nonstandard deceased-donor organs (Metzger et al., 
2003; Stratta et al., 2004; Woodside et al., 2012). While increased use of organs from 
living donors is one strategy to address the need for transplants, rates of live kidney 
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donation have not increased over the past decade. Data from OPTN shows that living 
kidney donation rate has in fact declined 17 percent from 2004 to 2014 (Matas et al., 
2015). The trend in decreasing living kidney donation has been shown among related 
donors, while participation in kidney paired donation (exchanges for incompatible pairs) 
and non-directed (e.g. unrelated) donation have increased since the National Organ 
Transplant Act was amended in 2007 allowing for these practices ("Charlie W. Norwood 
Living Organ Donation Act," 2007; Matas et al., 2015). 
As a small population within the healthcare system, living donors have 
contributed about 6,000 kidneys per year in the past 10 years but have made a significant 
impact. Living donor kidney transplants have better graft survival rates than transplants 
with deceased donor kidneys, significantly reduce the national waiting list, allow for 
incompatible kidney paired donation, and permit for preemptive renal transplantation 
prior to dialysis for ESRD (Matas et al., 2015; Waterman et al., 2015). 
Living Kidney Donor Follow-Up Policy 
The routine collection of short-term follow-up data on living donor outcomes is 
increasingly common. While to date most efforts focus on living donor clinical and 
laboratory data, psychosocial parameters, such as if the donor has returned to work, are 
also collected in the U.S. (OPTN, 2016b). In February 2013, the OPTN implemented 
policy requirements on living donor follow-up for all transplant centers in the United 
States. This was done in order to promote consistency in the informed consent process, 
medical and psychosocial evaluation, and medical follow-up received by living donors 
(OPTN, 2013). In 2014, OPTN requirements were incorporated within national health 
policies for living donors including liver and kidney-specific requirements. These health 
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policies created and approved by the OPTN/UNOS Living Donor Committee and 
subsequently the OPTN Board of Directors define minimum follow-up requirements 
(OPTN, 2016d), which can and should be expanded upon within center-specific protocols 
based on local experience and on a case-by-case basis.   
The data regarding short-term complications following donor nephrectomy are 
reliable according to reports from North and South America, Europe, and Asia (Lentine 
& Patel, 2012). Currently all OPTN/UNOS member transplant centers must submit living 
donor data at hospital discharge within 6 weeks after donation, whichever is earlier, as 
well as at 6 months, 1 year, and 2 years after donation. The submission of donor follow-
up information is required by OPTN through the two years post-donation, but the level of 
missing data in submitted forms does not improve their value (M. Dew et al., 2011; 
Ommen, LaPointe Rudow, Medapalli, Schröppel, & Murphy, 2011).   
Living donors with missing data on follow-up forms are more likely to have 
characteristics that increase their risk for future medical problems, including the 
development of hypertension and diabetes. In a survey of U.S. transplant programs, 
approximately 40% of lost contact with more than 75% of their donors by 2 years after 
donation (Waterman et al., 2013). In the same study, when asked about how long a 
donor’s health should be monitored post-donation, 31% of living kidney donor transplant 
program respondents endorsed 5 years or more, 30% endorsed 2 years, 32% endorsed 1 
year, and 8% endorsed 6 months or less. With the modifications to UNOS/OPTN policies 
implemented in 2013, all transplant centers with living donor programs must submit 
forms complete (i.e. without any missing information) for the majority of kidney donors 
(OPTN, 2016a).   
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The rationale for required follow-up for living kidney donors is at the foundation 
of the transplant system’s ethical obligation to ensure donor safety as well as the 
affirmative duty to provide ongoing data surveillance to inform future donors on the risks 
and benefits including long-term outcomes of donation. Comprehensive follow-up 
information of living donors’ health is limited. Recently a consensus conference on the 
follow-up care of living kidney donors suggested that specific registries or long-term 
research efforts should be devoted to the collection of a full range of living donor 
outcomes including psychosocial and financial outcomes and their relationships with—or 
increased risk due to—other medical outcomes (M. A. Dew & Jacobs, 2012). In addition, 
recommendations from the 2010 Living Kidney Donor Follow-Up Conference Writing 
Group included the need to capture information from sources beyond OPTN and linked 
data in order to improve the surveillance of comorbid conditions (Leichtman et al., 2011).   
Preventive and Primary Health Care Services for Living Kidney Donors 
New-onset morbidity takes years to emerge, making it unlikely that the 24-month 
or two-year short-term follow-up currently mandated by OPTN, UNOS, and the Centers 
for Medicare and Medicaid Services (CMS) provides a comprehensive preventive and 
primary health approach for living kidney donors. Data shows a minority of donors 
progressing to CKD, with some even requiring dialysis (Janki et al., 2015; Nazarian & 
Reese, 2015; Ross, 2015). New data suggests that when living kidney donor renal 
function declines, the decline occurs more than 5 to 7 years after the donation (Muzaale 
et al., 2014).  
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Therefore, with only minimal short-term assessment required by current health 
policies, living donors may go a long time without any preventive and primary healthcare 
services. Preventive and primary healthcare services are the favored environment for the 
management of corrective and preventative clinical measures for the living kidney donor. 
As with all CKD patients, regular and routine monitoring and laboratory testing can be 
viewed as an intervention that can delay or stop renal function decline with simple 
lifestyle modifications (Hallan et al., 2006).   
While OPTN/UNOS informed consent policy requires living donors are educated 
by the transplant center about the need for lifelong annual post-donation physical exams 
in primary care, two recent cross-sectional follow-up studies suggest that living donors 
are not engaging in the recommended preventative healthcare activities (OPTN, 2016c). 
A study of 103 African- American donors from two centers at an average of 6 years post 
donation showed that 41% were hypertensive; of these, over half (52%) were not 
receiving treatment and another 17% had inadequately controlled hypertension on 
medication (Doshi, Goggins, Li, & Garg, 2013). A 2012 study assessed 85 living kidney 
donors who averaged two years post donation at the time of the study for rates and 
correlates of health maintenance behaviors; among those studied, 68 living kidney donors 
had at least one regular medical checkup per year after donation (Myaskovsky et al., 
2012). Within this cohort, among the 68 living kidney donors who had post-donation 
check-ups, 6% reported that their blood pressure was not checked, 26% were not tested 
for diabetes or high blood glucose levels, and 35% reported not having their urine 
checked (Myaskovsky et al., 2012). Findings from these studies require verification that 
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could be accomplished with larger cohorts studied prospectively to improve our 
understanding of long-term living donor health monitoring and maintenance.  
 
Big Data and Living Kidney Donors 
Few studies have utilized big data sources external to the OPTN/UNOS and 
linkages with the Scientific Registry of Transplant Recipients (SRTR) to capture living 
kidney donor health data longitudinally. State Inpatient Databases (SID) provided by the 
Agency for Healthcare Research and Quality (AHRQ) that includes hospitalizations as 
well as standard diagnoses and procedure codes occurring during a hospitalization have 
been used to study living kidney donors (Schold et al., 2014). Schold et al. (2014) 
explored hospitalizations post-donation and compared them to other abdominal surgical 
procedures using data from patients in North Carolina, New York, Florida, and 
California. A limitation of a SID is the inability to track patients across different states 
limiting the study population to those patients who donated a kidney in the same state as 
their primary residence. This minimizes the possibility the SID would capture a 
hospitalization in multiple states. Furthermore this study using AHRQ SID data appeared 
to have high external validity for identifying living donors given the similarity to national 
data over the same time period (Schold et al., 2014). 
Linked OPTN and administrative private insurer data has been used to study 
health utilization and pharmacy claims of living kidney donors post-donation in order to 
assess anti-hypertension medication use (Lentine et al., 2014). While linked pharmacy 
and external payer data is novel, it is also beyond the scope of standard available 
transplantation datasets.  Limitations of using linked claims data include factors related to 
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the sample and outcome measures which were derived from insurance data; uninsured 
living donors are also not captured by this data source.  
The presented study will introduce a new source of data that has the potential to 
improve the frequency and quantity of living kidney donor follow-up. Adapted from a 
previous descriptive study of sources of ‘big data’ in organ transplantation (Massie, 
Kuricka, & Segev, 2014), Table 1.2 illustrates a summary of sources available for 
research in transplantation.  This adapted table includes the addition of a new clinical 
data source, Health Information Exchange (HIE).  
Table 1.2- Summary of Sources Available for Research in Transplantation  
Data Source Population 
Included 
Strengths Limitations Cost 
UNOS Transplant 
candidates and 
recipients; 
living and 
deceased living 
donors 
Linked to social security 
death master file; 
representative of total U.S. 
transplant population; 
longitudinal follow-up for 
transplant recipients 
Lacks comorbidities 
and longitudinal living 
donor data; does not 
ascertain kidney graft 
loss well 
Free 
SRTR Living and 
deceased 
donors; 
transplant 
candidates; 
transplant 
recipients 
Representative of total U.S. 
transplant population; 
longitudinal follow up for 
transplant recipients; ability 
to ascertain statistics on 
graft failure; supplements 
OPTN data with various 
secondary sources; 
ascertains kidney graft loss 
Does not contain 
robust longitudinal 
living donor data  
 
Standard 
analysis 
files 
(SAFs) 
available 
to 
researcher
s by 
request 
for fee 
USRDS All U.S. 
patients with 
ESRD requiring 
dialysis or 
kidney 
transplant since 
1995.  
Patient data regardless of 
access to transplantation; 
rich claims data; provides 
ESRD incidence for the 
entire U.S. population; 
longitudinal follow-up for 
transplant recipients 
Limited claims data 
(Medicare patients 
only) 
SAFs 
available 
to 
researcher
s with 
approved 
project 
proposals 
(for a fee) 
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AHRQ 
(National 
Inpatient 
Sample) 
Inpatients at 
20% sample of 
U.S. hospitals 
Patient demographics, ICD-
9-CM diagnoses and 
procedures; hospital 
charges; length of stay; 
discharge disposition; 
anynomized physician and 
hospital identifiers; hospital 
characteristics, rich in data 
unavailable in OPTN  
Created with a 
stratifying sampling 
mechanism (not 
necessarily an 
unbiased sample of 
transplant centers and 
transplant patients); 
lack of longitudinal 
information and 
limited to short-term 
hospitalization data; 
cannot be linked to 
OPTN data as 
identifiers cannot be 
released  
Available 
for 
purchase 
from 
AHRQ 
AHRQ (State 
Inpatient 
Database)  
Inpatients at 
hospitals in 47 
U.S. states and 
the District of 
Columbia 
Over 100 clinical and 
nonclinical variables 
included in a hospital 
discharge abstract 
Sample drawn from 
NIS; expensive and 
logistically complex 
for national studies  
Costs 
vary by 
State and 
data year 
External 
linkages 
Variable 
depending on 
external linked 
dataset (i.e. 
Pharmacy or 
private payer 
claims) 
Immunosuppression and 
other transplant related 
medication 
Challenging to link the 
data 
Costs 
vary 
University 
Health 
Consortium 
120 academic 
medical centers 
and 290 
affiliated 
hospitals in the 
U.S. 
Advantages for use in 
academic medical centers; 
focus on quality 
improvement activities 
No specific imperative 
to collect 
transplantation data 
Available 
to 
member 
institution
s 
HIE*  Variable based 
on the 
Participating 
institutions and 
providers 
Integrated, longitudinal data 
across participating 
providers extracted from 
electronic health records for 
large populations  
Varies per state Costs to 
providers 
to submit 
and 
access 
data; 
variable 
cost to 
researcher
s to access 
data 
*UNOS = United Network for Organ Sharing; SRTR= Scientific Registry of Transplant Recipients; USRDS = United 
States Renal Data Service; AHRQ= Agency for Healthcare Research and Quality; HIE =Health Information Exchange  
Table adapted from Massie, A. B., Kuricka, L. M., & Segev, D. L. (2014). Big data in organ transplantation: registries 
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and administrative claims. American Journal of Transplantation, 14(8), 1723-1730. 
 
Federal Incentives for Use of Health Information Exchange 
The enactment of the Health Information Technology for Economic and Clinical 
Health (HITECH) Act as part of the American Recovery and Reinvestment Act of 2009 
improved the adoption and use of electronic health records (EHRs) in the U.S. Thus, 
early on in the Obama Administration, the U.S. began to prioritize a focus on 
transforming healthcare delivery into a learning healthcare system that is patient-centered 
and value-based with supporting technical infrastructures (Aisner, 2007; Friedman, 
Wong, & Blumenthal, 2010).   
The Centers for Medicare & Medicaid Services already has a large role in 
encouraging HIE through existing Medicare and Medicaid programs and initiatives, as 
well as new programs authorized under the Affordable Care Act ("Patient Protection and 
Affordable Care Act, 42 U.S.C.," 2010). A timely interoperable health information 
exchange (HIE) at the state level is critical to the transformation of the U.S. healthcare 
system among a variety of healthcare stakeholders (clinicians, laboratories, hospital, 
pharmacy, health plans, payers and patients) (Brailer, 2005).  
According to the Healthcare Information and Management Systems Society, 
“Interoperability describes the extent to which systems and devices can exchange data, 
and interpret that shared data” (B. E. Dixon, 2016). Simply put, for two systems to be 
interoperable, they must be able to exchange data and subsequently present that data such 
that a user can understand it. EHR interoperability enables better workflow and reduced 
ambiguity, and allows data transfer among EHR systems and healthcare stakeholders. 
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Thus, EHRs can ultimately improve the delivery of healthcare by making the right data 
available at the right time to the right people.  
As it is expected that the requirements for living donor reporting will become 
more rigorous in the future, an exploration into the feasibility of using existing 
infrastructures such as HIE is timely (Keshvani et al., 2015). 
Health Information Exchange and the Indiana Network for Patient Care 
Interoperable EHRs are the foundational clinical data exchange to improve patient 
care. Health information exchange (HIE) is the general term which coveys how clinical 
information is shared across all providers of healthcare to support care delivery and 
encompasses strategies and technologies that can facilitate and enable coordinated and 
connected care across settings, which can improve health, healthcare delivery and cost 
(B. E. Dixon, 2016). Increasing providers’ capability to exchange information 
electronically with other providers has the potential to help address existing gaps in 
health information sharing between healthcare providers. This goal of improving care 
coordination is central to the concept of HIE.  
The Indiana Health Information Exchange (IHIE) makes statewide health record 
data available to physicians and researchers via the Indiana Network for Patient Care 
(INPC). The INPC was launched by Regenstrief Institute and is now supported by the 
IHIE (McDonald et al., 2005). As one of the oldest and largest health information 
exchange (HIE) infrastructures, the INPC has been shown to be a feasible data source to 
assess population health from electronic health records (EHR) (B. Dixon, Gibson, 
Frederickson, & Rosenman, 2014; B. E. Dixon, Whipple, Lajiness, & Murray, 2015) 
(Biondich et al., 2014). According to the Office of National Coordinator for Health 
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Information Technology an EMR contains the standard medical and clinical data 
gathered in one healthcare provider’s office. By contrast, an EHR goes beyond the data 
collected at the individual providers’ office and collects and includes a more 
comprehensive patient history (HealthIT.Gov).  
 The National Academy of Medicine defines the eight core functionalities of an 
EHR as: 1) health information and data, 2) result management, 3) order management, 4) 
decision support, 5) electronic communication and connectivity, 6) patient support, 7) 
administrative processes and reporting, and 8) reporting and population health (IOM, 
2003).    
 Starting in 1980, the INPC contains 17.2 million individual patients, 4.6 billion 
clinical observations, and 165 million text reports capturing 68% of the state population 
in 2014. The INPC has institutional participation from over 80 hospitals in the state, 
major health networks, and major health insurance provider data, making the 
comprehensive statewide HIE well suited for research possibilities into project feasibility 
and allows for the construction of datasets for analysis (B. E. Dixon, 2016).  
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CHAPTER TWO: THEORETICAL FRAMEWORK 
This chapter presents the guiding theoretical framework used to study living 
kidney donors in a statewide health information exchange (HIE). The chapter discusses 
important concepts of health policy and management and describes the context in which 
this dissertation is studied.  
Health Policy and Management 
Public and population health can be influenced by various policies. The World 
Health Organization (WHO) defines health policy as “decisions, plans, and actions that 
are undertaken to achieve specific healthcare goals within a society” (WHO, 2016). 
According to the WHO, an explicit health policy can achieve many things, including a 
vision for the future that helps to set goals and metrics for the short, medium, and long-
term. Furthermore, health policy outlines priorities and expected roles of different groups 
while building consensus and informs people. The U.S. Centers for Disease Control and 
Prevention defines ‘policy’ as a law, regulation, procedure, administrative action, 
incentive, or voluntary practice of governments and other institutions (CDC, 2015).  
As healthcare is complex and dynamic, leaders must consider both internal and 
external influences that impact resources and activities of an organization. Health 
services administration and management has a role in health policy. One of the crucial 
areas for managing external influences is to be knowledgeable about health policy 
matters at the local, state and federal levels (Thompson, Buchbinder, & Shanks, 2005).  
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Health Services Research  
‘Health services research’ (HSR) is defined by AcademyHealth as the 
multidisciplinary field of scientific investigation that studies how social factors, financing 
systems, organizational structures and processes, health technologies, and personal 
behaviors affect access to healthcare, the quality and cost of healthcare, and ultimately 
our health and well-being (AcademyHealth, 2012). Within HSR, the domains include 
individuals, families, organizations, institutions, communities, and populations, and were 
first presented in the 2002 Agency for Healthcare Research and Quality definition of 
HSR (AHRQ, 2015). 
Donabedian Framework 
The Donabedian Framework has been foundational to research in health services 
(Donabedian, 1966, 1978, 1988). In 1988 Donabedian (pg.1783) noted, “As we seek to 
define quality, we soon become aware of the fact that several formulations are both 
possible and legitimate.” Therefore quality measurement in healthcare can also be viewed 
as non-standardized (Pronovost, Miller, & Wachter, 2007). However, the standard 
conceptual model of healthcare quality that is most heavily cited is Donabedian 
(Donabedian, 1966, 1978, 1988). The Donabedian framework lays out three constructs of 
quality in causal fashion: structure, process, and outcome (Figure 2.1).  
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Figure 2.1: Donabedian 3-Factor Conceptual Framework of Quality 
 
*Adapted from Donabedian, 1988 
 
In the Donabedian conceptual model, structure pertains to all capital that enables 
delivery of care including human, cultural, physical, but is not sufficient for the delivery 
of health services (Campbell, Fitzpatrick, Haines, & Kinmonth, 2000). Processes of care 
is often codified in clinical practice guidelines and can be measured as adherence as 
standard procedures which are recommended for a patient’s condition. Process is the 
actual delivery of care and can be further broken down into technical and interpersonal 
dimensions (Blumenthal, 1996; Campbell et al., 2000; Donabedian, 1988; Steffen, 1988). 
Technical care is the application of clinical medicine to a personal health problem 
(Campbell et al., 2000; Donabedian, 1978) and is widely viewed as a credible measure of 
service quality for empirical research (Jha, Li, Orav, & Epstein, 2005). Interpersonal care 
can be seen as the interaction between the patient and members of the healthcare system 
and is a complementary measure of service quality (Fenton, Jerant, Bertakis, & Franks, 
2012).   
According to Donabedian (1988, pg. 1744) “interpersonal process is the vehicle 
by which technical care is implemented and on which its success. Therefore, the 
management of the interpersonal process is to a large degree tailored to the achievement 
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of success in technical care” (Donabedian, 1988). Finally, the Donabedian model focuses 
on outcomes, which are intended to measure patient health status after the service 
encounter (Donabedian, 1988). There are many outcome measures, (e.g. symptoms, 
quality of life, functional status, cost, post-care complications, risk-adjusted mortality and 
readmission rates, etc.) but not all are suitable for measuring delivered service quality 
(Krumholz et al., 2000).   
Henderson Conceptual Model for Living Kidney Donor Follow-up 
 Adapting the Donabedian 3-factor conceptual framework of quality, a new model 
is presented to understand how structures of care, processes of care and outcomes are 
applied to living kidney donor follow-up. Figure 2.2 illustrates the Henderson Conceptual 
Model for Living Kidney Donor Follow-up. The structures of care can be viewed as both 
the national organ transplant system as well as the individual transplant centers 
performing the living donor transplant surgery that is responsible for reporting follow-up 
to the Organ Procurement and Transplantation Network under the United Network for 
Organ Sharing policies. Processes of care for living kidney donor follow-up can be 
viewed as both internal and external to the transplant center that is responsible for 
reporting; while transplant centers encourage living kidney donors to return to the 
transplant center for follow-up care, primary care supports the process of care from an 
external perspective. Outcomes for living kidney donor follow-up can be viewed as both 
short and long-term and vary in measures based on policy requirements and principles of 
prevention. 
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Figure 2.2 The Henderson Conceptual Model for Living Kidney Donor Follow-Up 
                              
 
*TxC stands for Transplant Center 
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Original Contribution 
This dissertation will contribute to the existing literature by improving the 
understanding and impact of health information exchange (HIE) on retrospectively 
identifying presumed living kidney donors, understanding follow-up care patterns, and 
examining their health outcomes. Current processes often yield incomplete and untimely 
reporting across transplant centers requiring time-consuming efforts needed in the years 
after donation. New approaches are needed which will capitalize on new technology and 
new datasets in order to better understand new ways that living donor follow-up data can 
be collected. Given their significance to preventive care for long- term living donor 
health and safety, collecting high-quality, reliable, complete and timely data merits 
ongoing attention and quality improvement efforts.  Additionally, there is evidence of 
growth with respect to implementation of information systems within public health (B. E. 
Dixon et al., 2015).  This study is the first one to utilize HIE as a novel data source to 
study living kidney donation outcomes.   
The dissertation seeks to address three distinct, but related, research questions 
which include: 1) Can a cohort of living kidney donors be retrospectively identified in a 
statewide HIE? 2) What follow-up care patterns are demonstrated in the HIE for the 
living kidney donor cohort? and 3) What clinical follow-up outcomes are associated with 
presumed living kidney donors in the identified cohort?  
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CHAPTER THREE: IDENTIFYING LIVING KIDNEY DONORS IN A STATEWIDE 
HEALTH INFORMATION EXCHANGE 
Abstract 
Background: Providing follow-up care for living kidney donors (LKDs) is an important 
responsibility that the transplant community must assume, but patients are often lost-to-
follow-up.  
Objective: This study sought to identify a cohort of LKDs in a repository of integrated, 
longitudinal medical records gathered using health information exchange (HIE) across a 
network of health systems.  
Methods: Using a text-mining approach involving plaintext clinical notes, we identified a 
cohort of 1,245 LKDs. The cohort was refined by age exclusion based on transplant 
center level data.  
Results: The LKD cohort identified showed high correlation with Organ Procurement and 
Transplantation Network LKD frequency by year (r = 0.948), demonstrating that the 
methodology was effective for our sample population.  
Conclusion: As HIE efforts expand across the nation, these repositories are valuable 
sources that be further explored for use in clinical and research scenarios to improve 
follow-up and involving patients who span many care providers.   
Keywords: Registry-based studies; retrospective studies; living kidney donors; health 
information technology 
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Introduction 
According to Organ Procurement and Transplantation Network and United 
Network for Organ Sharing (OPTN/UNOS) data, there were 5,074 living kidney donors 
(LKDs) in 2015. Follow-up care for LKDs is paramount for patient safety and to promote 
national trust in the organ transplant system. Follow-up care at the transplant center has 
been required by OPTN/UNOS Policy 18 for two years post donation since 2013, with 
annual follow-up in primary care as the current clinical practice recommendation (D. A. 
Mandelbrot & Pavlakis, 2012; OPTN, 2016a). While difficult to achieve, successful 
strategies have been proliferated, recognizing that follow-up and continuity of care for 
LKDs is vital to the ethical obligation transplant centers have to promote patient safety in 
living donation (Dew et al., 2011). In addition to maintaining compliance with post-
donation follow-up care policy, the ability to follow-up with LKDs post-donation 
provides organ transplant researchers and epidemiologists an opportunity to better 
understand the risks and sequelae of living donation thus ultimately improving informed 
consent. 
Organ transplant data as a whole is traditionally robust, but is limited in the area 
of living donation. While nationally maintained data sources such as OPTN/UNOS 
(which provides data for the Scientific Registry of Transplant Recipients (SRTR)) are 
available, limitations in regards to living donation exist (Massie, Kuricka, & Segev, 2014; 
J. Schold et al., 2015). This is because prior reports have indicated a lack of complete 
reporting of LKD follow-up on standard OPTN/UNOS forms; follow-up is also highly 
variable by transplant center (D. Mandelbrot et al., 2007; D. A. Mandelbrot et al., 2009; 
J. Schold et al., 2015; Amy D Waterman et al., 2013).  
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Health information exchange (HIE) is the electronic transfer of clinical and 
administrative information across diverse and often competing health care organizations 
(Dixon, 2016). With a significant increase in the availability and use of HIE by hospitals 
catalyzed by federal policy (Blumenthal, 2010; Furukawa, Patel, Charles, Swain, & 
Mostashari, 2013), communities are developing the capability to exchange a wide range 
of data to support a growing number of purposes in health care delivery and public 
health. Previously, HIE has been shown to hold promise for population health 
measurement and tools from the discipline of clinical informatics, such as natural 
language processing (NLP), can be used in conjunction with HIE to develop cohorts for 
outcomes research (Dixon, Gibson, Frederickson, & Rosenman, 2014; Wang et al., 
2015).  
As HIE can connect components of the health system together in an effort to 
improve care coordination, HIE networks may be mechanisms in which a transplant 
center can identify donors who might otherwise be lost-to-follow-up. The objective of 
this feasibility study is to present a novel method for retrospectively identifying LKDs in 
a statewide HIE repository with tools from the discipline of clinical informatics. We 
describe HIE networks as a new clinical data source and the cohort identification process 
that has the potential to be replicated nationwide to improve LKD follow-up, 
coordination, and continuity of care.  
Methods 
Data source 
The Indiana Network for Patient Care (INPC) represents one of the largest HIE 
networks in the country with over 100 separate healthcare entities providing data and 
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includes: major hospitals, health networks, and insurance providers (Biondich & Grannis, 
2004; Overhage, 2016).  The INPC also includes outpatient data from participating 
physician offices, community health and indigent care centers, county and state public 
health departments, national laboratories, payers, and ancillary sources such as radiology 
systems (Biondich & Grannis, 2004; McDonald et al., 2005). When combined, the 
information from these institutions represent data on over 17 million patients in the form 
of 4.9 billion clinical observations, 951 million encounter records, and over 195 million 
plaintext reports (Institute, 2015). The INPC is used by clinicians to facilitate real-time 
access to past medical history, and the associated HIE repository also facilitates access to 
data for researchers (Dixon, Whipple, Lajiness, & Murray, 2015; Dixon BE, 2016).  
Patient Population 
We sought to retrospectively identify LKDs from Indiana University Health, one 
of the participants in the INPC, between January 1, 1998, and July 22, 2015. Based on 
data from July 30th, 2015, Indiana University Health (formerly Clarian Health) has 
performed 90% of all LKD transplants in the state to date since the OPTN began 
collecting data in 1988 (1,708 out of 1,888 total living donor kidney transplants). The 
other transplant centers in the state, Lutheran Hospital in Fort Wayne and St. Vincent’s 
Hospital in Indianapolis, did not begin performing LKD transplants until 2007 and 2009, 
respectively, according to 2015 OPTN annual state-level data.  
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Cohort Identification 
We used a combination of traditional and advanced methods to identify the LKD 
cohort as summarized in Figure 3.1. First, we employed a traditional health services 
research method of using administrative data, International Classification of Diseases 
Clinical Modification Ninth Revision (ICD-9-CM) diagnostic and Current Procedural 
Terminology (CPT) codes that are routinely captured in the INPC as patients traverse the 
health system. While administrative codes are sensitive, they are not specific enough to 
distinguish LKDs from other populations in the INPC such as deceased kidney donors 
and kidney transplant recipients. Therefore we developed a text-mining algorithm to 
identify LKDs within plaintext reports (e.g., clinical notes) using the Regenstrief NLP 
Tool® that employs dictionary-based named entity recognition. The text-mining 
algorithm uses a series of keywords as inputs to a process that searches across a set of 
plaintext reports to identify LKDs. The text-mining algorithm uses language from the 
Unified Medical Language System and considers spelling variants as well as negation 
when evaluating the contents of a plaintext report. Pre-processing (spell check, removal 
of duplicate characters, application of grammar rules) for word sense-disambiguation, 
lexical tokenization (breaking text into words, phrases), negation handling (detecting if 
an expression is negative), and stemming for word classification (i.e. wait – waiting) 
were included. (Bodenreider, 2004; Bushinak, AbdelGaber, & AlSharif, 2011; Lindberg, 
Humphreys, & McCray, 1993; Rink, Harabagiu, & Roberts, 2011; Witten & Frank, 
2005). Appendix A contains the complete list of terms used to create the text-mining 
algorithm. The cohort was refined using transplant center data; we excluded records by 
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restricting for patient age (>67 years old), as the oldest recorded donor, according to IU 
Health records, would be age 66. 
Figure 3.1 Cohort Identification Process 
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Cohort Validation 
To validate that the cohort contained valid electronic health records for LKDs, we 
randomly sampled 100 (8%) unique patients for manual chart review. An experienced 
data analyst at the Regenstrief Institute familiar with INPC data examined patient charts 
to confirm that the individual was indeed a LKD as opposed to a deceased kidney donor 
or evidence of another medical purpose such as renal carcinoma. Counts of LKDs by year 
were compared to the publically available OPTN database which is the national ‘gold 
standard.” OPTN data on LKDs come from a registration form submitted by the 
transplant center when they enter the transplant system.  
 
Data Analysis 
Pearson’s correlation was performed to compare the INPC derived cohort of 
presumed LKDs with OPTN yearly counts. Analysis was carried out using SPSS, version 
23 (IBM SPSS Statistics, Inc.). This study was approved by the Indiana University 
Institutional Review Board Study # 1506003825. 
 
Results 
Cohort Identification and Internal Validation 
We identified 6,521 unique patients with ICD-9-CM V59.4 for ‘Kidney Donor’ 
using administrative data captured in the INPC. We attempted to also use CPT code 
50320 for ‘Remove Kidney Living Donor,’ but it had never been used in INPC. The 
frequency of ICD-9-CM code V59.4 are presented by location in INPC in Table 3.1. The 
top three most frequent locations where ICD-9-CM V59.4 appear in INPC include 
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discharge diagnosis (N = 22,484) and hospital diagnosis (N = 16,712), and admitting 
diagnosis counts (N = 6,362). This administrative code only appeared 58 times in clinic 
billing diagnosis.  
Table 3.1 Frequency of ICD-9-CM V59.4 by Health Information Exchange Location  
Locations  Count 
Discharge diagnosis 22,484 
Hospital diagnosis 16,712 
Admitting diagnosis 6,362 
Initial diagnosis 158 
Clinic billing diagnosis 58 
Diagnosis & complaints 45 
Hospital diagnosis  2 
Source: Indiana Network for Patient Care (1998-2014) 
 
 
The text-mining algorithm identified 1,253 unique patients. Of these patients, 
1,196 (95%) also had an ICD-9-CM code v59.4 for Kidney Donor in their administrative 
records. Refining the cohort with transplant center data excluded eight patients based on 
age at time of donation (>67 years old), resulting in a final cohort of 1,245 presumed 
LKDs. Out of the 100 records sampled for internal validation, only one patient (1%) was 
not confirmed to be a LKD.  
Validation Against External Data 
Pearson’s correlation showed a strong positive correlation between the INPC 
presumed LKD cohort and OPTN yearly counts (r = 0.948; p <0.00001). Table 3.2 shows 
INPC presumed LKD counts by year and the corresponding proportion of OPTN counts.  
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Table 3.2 Presumed Living Kidney Donor Cohort by Year and Proportion of 
Expected  
Year HIE a 
 
OPTN b Proportion of Expected  
1998 39 50 78% 
1999 55 49 112% 
2000 53 58 91% 
2001 61 65 94% 
2002 68 67 101% 
2003 58 59 98% 
2004 81 80 101% 
2005 80 76 105% 
2006 108 107 101% 
2007 83 85 98% 
2008 91 90 101% 
2009 105 112 94% 
2010 104 104 100% 
2011 84 83 101% 
2012 62 62 100% 
2013 72 72 100% 
2014c 41 65 63% 
Source: Indiana Network for Patient Care (1998-2014) 
N = 1,245  
Notes:  
HIE = Health Information Exchange data from the Indiana Network for Patient Care 
OPTN = Organ Procurement and Transplantation Network living kidney donor counts at the center level 
based on July 31st, 2015  
 
 
Cohort Demographics  
The median and interquartile range (IQR) age at donation was 40.4 years (32-49) 
(range=19-66). Table 3.3 presents cohort demographics and by age, sex, and race. The 
majority of presumed LKDs were white 87.9%, 89 (7.9%) were Black or African-
American, and 26 (2.2%) were Hispanic. There were 27 (2.2%) reported as ‘other’ or 
‘unknown’ race and only one presumed LKD reported as Asian and one as Native 
Hawaiian or Pacific Islander. Six (0.5%) had missing racial data.  
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Table 3.3 Presumed Living Kidney Donor Cohort Demographics  
 Mean  S.D. 
 
Age 
 
40.4 10.7 
     Female  
     (N = 739) 
41.8  10.4 
     Male 
     (N = 506) 
 
38.5 10.7 
 
Race 
 
  
     White 
     (N = 1,094) 
41.0 10.6 
     Black  
     (N = 89)  
36.2 9.8 
     Hispanic 
     (N = 26) 
34.4 9.4 
     Asian  
     (N =1) 
+ + 
     Native-American 
     Pacific Islander  
     (N =1) 
+ + 
Source: Indiana Network for Patient Care, 1998-2014 
Notes: + category is too small to report values 
 
 
Discussion 
We present a novel method for the identification of LKDs from an HIE network 
that might be otherwise lost-to follow-up. This feasibility study makes an important step 
forward in understanding how LKDs who may have already left the transplant system for 
care can best be identified for follow-up and coordination of care. Our identification 
method resulted a cohort of 1,245 LKDs who donated a between 1998 and 2014 for 
which we were able to validate against national registry data which is the current gold 
standard. Text-mining was preferred over ICD-9-CM administrative code v59.4 for 
identifying LKDs in INPC. In our sample, ICD-9-CM administrative coding did not 
allow for the easy identification of LKDs. ICD-9-CM codes were not specific enough for 
identifying LKDs from other populations, including deceased kidney donors, recipients 
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of a kidney transplant, and patients undergoing nephrectomy for presumed other causes. 
Our text-mining algorithm allowed for the identification of LKDs that significantly 
correlates with LKD counts reported nationally by the OPTN providing confidence in our 
methodology.  
Implications for LKD cohort identification using a HIE network can improve how 
individual centers and the national transplant community nationally provide follow-up, 
surveillance, care coordination, and continuity of care. In 2011, a consensus conference 
of experts emphasized the importance of long-term follow-up of living donors and 
concluded that living donor follow-up would be improved with more data from different 
sources and mechanisms for better data collection, submission, and analysis of data on 
live donors (Leichtman et al., 2011). As a new data source for transplant centers, we 
believe HIE could help improve follow-up reporting, data collection, and continuity of 
care. HIE could also reduce significant barriers reported that prevent longitudinal follow-
up such as including inconvenience, lack of donor desire for follow-up at the transplant 
center, and out-of-date donor contact information (Amy D Waterman et al., 2013). We 
view the current federal incentives for meaningful use and interoperability of electronic 
health records to be supportive of the expert recommendations set forth in 2011 to 
improve living-donor follow-up care (Leichtman et al., 2011; Office of the National 
Coordinator for Health Information Technology & Human, 2010).  
HIE networks contain integrated clinical data both internal and external to the 
transplant center, which represents two processes of care for LKD follow-up and the 
opportunity to examine both short and long-term outcomes (See Chapter 3, Conceptual 
Framework). Cohort identification through HIE presents an new opportunity to 
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investigate post-donation outcomes in living donors by understanding their follow-up 
care patterns at the transplant center for the two year period following the donation, as 
well as the care they receive external to the transplant system. Previously, external data 
sources such as pharmacy and private claims data have been previously linked with 
OPTN data in order to study depression, cancer diagnosis, post-donation narcotic use, 
and morbidity associated with racial variation in living kidney donors (Lentine et al., 
2015; Lentine, Schnitzler, et al., 2012; Lentine et al., 2010; Lentine, Vijayan, et al., 
2012).  
With nearly half of U.S. hospitals currently participating in data sharing with 
EHRs and several others are working towards building this capacity (Adler-Milstein, 
Bates, & Jha, 2011), improving identification, follow-up and care continuity for LKDs 
will become easier. In addition, large transplant centers might collaborate to create a 
clinical data and patient-powered research network for LKDs, which are currently 
receiving attention and large financial investments As an example, the Patient Centered 
Outcomes Research Institute recently approved $142.5 million in funding to support 34 
clinical research data networks supported through integration with the National Patient-
Centered Clinical Research Network (PCORnet), a highly representative, national 
network for conducting clinical outcomes research (Fleurence et al., 2014; Stencel, 
2015). 
There are limitations that deserve mention in this feasibility study. First, we were 
limited in identifying LKDs in 2014 because of a time lag in the Regenstrief NLP Tool®. 
We ran the text-mining algorithm in July of 2015, but the last unique LKD we retrieved 
had a donation date in May of 2014. This limitation resulted in the proportion of expected 
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LKDs for this year being lower than if we were able to include donors through December 
of 2014; the yearly donor count in OPTN included the entirety of 2014. Second, while we 
believe that the validation for our cohort identification method was reasonable in this 
feasibility study, future studies should investigate formal F-measures performing 
sensitivity and specificity analysis to attain performance characteristics (precision, recall, 
accuracy) of the text-mining algorithm. Recall, or sensitivity, is the percentage of LKDs 
that were correctly identified by the algorithm. Precision, or positive predictive value, is 
the percentage of LKDs identified by the algorithm that are correct. F-measure is the 
harmonic mean of precision and recall, and provides a measure of overall accuracy 
(Chowdhury, 2010; Manning, Raghavan, & Schütze, 2008; Manning & Schütze, 
1999).Finally, this feasibility study was limited to one transplant center and one HIE. The 
Indiana Health Information Exchange is a nationally recognized example of an advanced 
HIE infrastructure. Thus, the generalizability of using this data source is a potential 
limitation as other states have less robust infrastructures. However, the financial incentive 
to build out these exchanges exists nationwide (Adler-Milstein & Jha, 2012). Over half a 
billion dollars has been invested into state governments to support the technical 
development of HIE since 2009 (Williams, Mostashari, Mertz, Hogin, & Atwal, 2012). 
There are 56 current development projects to create similarly scaled infrastructures to 
support meaningful use and interoperability standards (HealthIT.Gov, 2014). For 
example, in New York where there were 510 LKDs in 2014, (10.8% of 5,538 total living 
kidney donations) adoption of HIE has been increasingly popular. In a statewide survey, 
some 98% of responding New York hospitals (N = 126) had implemented or begun 
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implementing an EHR which is greater than a fourfold increase in three years (Abramson, 
Silver, & Kaushal, 2014).  
Currently, mechanisms and the authority exist for the Health Resources and 
Services Administration (HRSA) to fund long-term living donor data collection within 
the existing SRTR database. There is now an unambiguous endorsement from the 
transplant community supporting the clinical, scientific and administrative necessity to 
begin the development of a national registry. As reported at the November 17th 2015 
public meeting of the Advisory Committee on Organ Transplantation, with the recent 
renewal of the federal contract the SRTR is now conducting a feasibility study for the 
development of a National Living Donor Registry with initial results due to HRSA in 
June of 2016 (Kaiskie, 2015). At the time of this writing, the SRTR is currently 
concluding the study (Personal Communication from SRTR, April 5th, 2016). Future 
investigations into the legal barriers and data use agreements in order to link datasets 
populated with HIE with existing SRTR to better understand the approximately 100,000 
LKDs currently living in the United States is warranted.   
Conclusion 
This feasibility study of a novel method for LKD cohort identification in HIE can 
enable transplant centers to find donors who might otherwise be deemed as lost-to-
follow-up. Future research should formally assess the validity of the text-mining 
algorithm for the identification of LKDs when applied to another statewide HIE. As an 
existing infrastructure that enables pooled clinical data to improve care continuity, HIE 
can impact both processes and outcomes of follow-up care for LKDs. HIE data 
applications could also be useful in developing control cohorts for improved research on 
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long-term health outcomes such as demonstrating LKD longitudinal donation renal 
function trajectories and assessing the effectiveness of center-level screening of LKD 
candidates.  
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CHAPTER FOUR: LIVING KIDNEY DONOR FOLLOW-UP IN A STATEWIDE 
HEALTH INFORMATION EXCHANGE 
Abstract 
Background: Follow-up care is important to promote patient safety and informed consent 
for living kidney donors (LKDs), but has been historically difficult to achieve. In 2013, 
the Organ Procurement and Transplantation Network/United Network for Organ Sharing 
implemented policy requiring that transplant centers provide two-year follow-up care for 
LKDs.  
Objective: To assess receipt of 24-month (two-year) follow-up and differences by race 
and age in a cohort of LKDs identified in a health information exchange. 
Participants: Electronic medical records of 1,245 patients 19 - 66 years old who donated a 
kidney between 1998 and 2014.  
Methods: Binomial logistic regression was performed to ascertain the effects of age and 
race on receipt of 24-month follow-up controlling for the era in which the donation year 
occurred.  
Outcome Measures: Receipt of 24-month follow-up was measured by timely and 
complete 24-month follow-up kidney laboratory data. Serum creatinine (SCr) and 
urinalysis (UA) were binary dependent categorical variables (yes/no).  
Results: LKDs between the ages of 40 – 49 have are 1.3 times more likely of having 24-
month follow-up, while those aged 50 – 59 are 1.8 times more likely as compared to 19-
39 year olds. LKDs in the third donor era (2009-2012) were 65.1 times more likely to 
have 24-month follow-up than those who donated before 2004 while those LKDs in the 
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fourth era (2013-2014) were 22.2 times more likely than those donating between 1998 
and 2004 to receive 24-month follow-up (p = 0.000). Black or African-American LKDs 
were about twice as likely than those non-black or African-Americans to have 24-month 
follow-up (p = 0.014).  
Conclusions: This study provides previously unknown information about historical trends 
and differences in LKD follow-up care by age and race, where the most significant 
differences on receipt of 24-month follow-up was age. Knowledge of age-related 
differences in LKD follow-up care patterns at the transplant center level can assist 
research teams in the design and development of interventions to improve care and 
patient outcomes.  
Keywords: living donation, health services, and registry-based studies 
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Introduction 
There are over 5,500 living kidney donors (LKDs) entering the organ transplant 
system each year, but historically follow-up care has been difficult to achieve. The 
benefits of LKD follow-up include improved information that can be communicated to 
prospective donors about risks of donation, improved health and outcomes for living 
donors nationally, and improved national trust in the living donation process (Amy D 
Waterman et al., 2013). The Organ Procurement and Transplantation Network 
(OPTN)/United Network for Organ Sharing (UNOS) has collected follow-up data on 
living donors at 6 months and 12-months (1-year) post-donation since 1999, including 
information on serum creatinine (SCr), blood pressure, and body mass index (Brown Jr, 
Higgins, & Pruett, 2009). Although the OPTN/UNOS was collecting short-term follow-
up data on living donors, one study revealed that in 2006 50% of LKDs had incomplete 
complication data at one year, and approximately one-third of LKDs were reported “lost 
to follow-up” (Klein et al., 2010).  
In an effort to improve follow-up care patterns nationally, the OPTN implemented 
new policy requirements for transplant programs in in order to promote consistency in the 
informed consent, medical and psychosocial evaluation, and follow-up of living donors in 
February of 2013. These new policies required transplant centers to submit ‘timely and 
complete’ follow-up including clinical and laboratory data for LKDs at the following 
three time points post-donation: 6-months, 12-months, and 24-months (OPTN, 2016d). 
‘Timely and complete reporting and submission of data is defined by the OPTN as 60 
days before or after the 6-month, 12-month, or 24-month anniversary of the donation 
date. Under the new OPTN/UNOS policy implemented in 2013, transplant centers must 
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report accurate, complete and timely follow-up data for donor status and clinical 
information for at least 60% of LKDs who donate between February 1, 2013 and 
December 31st 2014, 70% of LKDs who donated between January 1, 2014 and December 
31st 2014, and 80% of LKDs who donated after December 31st 2014. In addition to donor 
status and clinical information, complete and timely follow-up for kidney laboratory data 
for at least 50% of LKDs who donate between February 1, 2013 and December 31st 2014, 
60% of LKDs who donated between January 1, 2014 and December 31st 2014, and 70% 
of LKDs who donated after December 31st 2014 is mandatory. The required kidney 
laboratory data for follow-up includes serum creatinine (SCr) and urine protein (OPTN, 
2016d). Two year, or 24-month follow-up is now considered to be the standard of care 
for all prospective donors and is considered the final required routine follow-up care visit 
to the transplant center before the LKD is released to the care of their primary care 
physician.  
Nationally, efforts are being made to identify morbidity in the postoperative 
period and to facilitate the potential need for post-donation interventions for LKDs 
including those aimed at improving follow-up (A. X. Garg et al., 2012; H. N. Ibrahim et 
al., 2009; Lentine & Patel, 2012; P. Reese et al., 2014; Segev et al., 2010). These national 
efforts including the ability to monitor, identify, and facilitate population health 
management of LKDs at the transplant center-level has historically been limited by lack 
of infrastructures and processes in order to collect clinical data long after the short term 
surgical complication period has ended. As the ideal approach to capturing clinical data 
to improve knowledge about LKD health outcomes undergoes increasing debate amongst 
the transplant community and regulatory bodies, it is prudent to investigate new clinical 
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data sources including statewide health information exchange (HIE). As these new 
sources are available providing LKD data, patient level differences in follow-up care 
patterns can now be examined. Examination of follow-up care patterns can improve 
population health management and support the design of targeted interventions to 
improve post-donation follow-up at the transplant center level. The objective of this 
retrospective cohort study is to assess receipt of 24-month follow-up for LKDs including 
differences in race and age.  
Methods 
Data Source 
INPC is the database of clinical and other information that is exchanged though 
the Indiana HIE and is derived from a variety of pooled Electronic Health Record (EHR) 
systems (Biondich & Grannis, 2004). INPC represents one of the largest patient networks 
in the country with over 100 separate healthcare entities providing data including: major 
hospitals, health networks, and insurance providers. INPC also includes outpatient data 
from participating physician offices, community health and indigent care centers, county 
and state public health departments, national laboratories, payers, and ancillary sources 
such as radiology systems (Biondich & Grannis, 2004; McDonald et al., 2005). When 
combined, the pooled information from these institutions represent data on over 17 
million patients in the form of 4.9 billion clinical observations, 951 million encounter 
records, and over 195 million multimedia reports (Institute, 2015).  
Study Participants 
Indiana University Health is one of three operational transplant centers in the state 
of Indiana and has performed over 90% of living kidney donor transplants since the 
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OPTN began collecting data in 1988. Assessment of 24-month follow-up included 1,245 
LKDs with a donation date between January 1998 and May 2014. The Indiana University 
Institutional Review Board Study approved this study #1506003825.  
Outcome Measures 
Receipt of 24-month follow-up was measured by kidney laboratory data and 
included serum creatinine (SCr) and urine protein measured by a urinalysis (UA) (OPTN, 
2016e). In accordance with what is written in OPTN/UNOS policy, timely and complete 
follow-up laboratory data was defined as within 60 days of the 24-month donation 
anniversary.  
Independent Variables 
 Age categories were defined as 19-39 years old, 40-49 years old, 50-59 years old, 
and age 60 and over. Race was classified as either African-American or non-African-
American (including Asian, Native American Pacific Islander, or White); ‘Null or code 
not mapped’ and ‘other or unknown’ were marked as missing data. Donation era was 
calculated based on year of donation and was stratified by four categories where 1998-
2004 was the first donor ear; 2005-2008 was the second; 2009-2013 was the third; and 
2013-2014 was the fourth.  
Data Analysis 
The yearly proportion and frequency of LKDs with follow-up kidney laboratory 
data was identified in INPC for each donation year represented by the cohort. Binomial 
logistic regression was performed to assess receipt of 24-month     follow-up differences 
including age and race while controlling for the era in which the donation year occurred. 
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A sensitivity analysis was conducted whereby donation year was categorized in multiple 
ways and is presented in Appendix B. This analysis was done due to the belief that there 
may be complex relationships between receipt of follow-up and time. First, there is a 
known increase in follow-up rates over time (Parente et al., 2015; J. Schold et al., 2015). 
Second, INPC data may be more complete over time, with a particular increase in 
completeness occurring in 2004 when the Indiana Health Information Exchange became 
incorporated and its infrastructure improved. Therefore, our sensitivity analyses 
categorized donation year in multiple ways in an attempt to account for these time trends 
and minimize confounding in our estimation of the relationship between receipt of 
follow-up and age and race. All data management and analyses were carried out with 
SPSS, version 23 (IBM SPSS Statistics, Inc.) and SAS, version 9.3 (SAS Institute, Cary, 
NC, USA) with a 95% confidence level where (p  <0.05) is considered significant. 
 
Results 
The median interquartile range (IQR) age at donation for the cohort (N = 1,245) 
was 40.4 years (32-49). There were 739 female (59.4%) and 506 male (40.6%) LKDs and 
89 (7.0%) were Black or African-American. There were 392 (31.4%) LKDs with 24-
month SCr follow-up kidney laboratory data but only 40 (3.1%) had 24-month UA 
follow-up kidney laboratory data. As illustrated in Table 4.1, 2012 had the highest 
proportion of LKDs (79.4%) with 24-month SCr follow-up kidney laboratory data. There 
was no donation year with greater than a 7% proportion of LKDs with 24-month UA 
follow-up kidney laboratory data as shown in Table 4.2. 
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Binomial logistic regression models were analyzed to predict receipt of 24-month 
follow-up using age at time of donation, race, and donation era as predictors. Table 4.3 
presents crude age and race differences in 24-month follow-up laboratory data. For 
receipt of 24-month follow-up as measured by SCr kidney laboratory data, a test of the 
full model against a constant only model was statistically significant, indicating that the 
predictors as a set reliably distinguished between LKDs with 24-month follow-up SCr 
laboratory data (chi square = 434.171, p <0.000 with df = 7, Nagelkerke’s R2 = .0.422). 
Prediction success for the 24-month follow-up SCr laboratory data was 78.1%. The Wald 
criterion demonstrated that the age variable made a significant contribution to the 
prediction (p = 0.003). Results of the binomial regression for receipt of 24-month follow-
up as measured by SCr kidney laboratory data is presented in Table 4.4.  
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Table 4.1 Living Kidney Donor Follow-Up at 6-month, 12-month and 24-months: 
Serum Creatinine  
Donation  
Year 
Total LKDs 
in Year 
6 –month SCr 
 
12 –month SCr 
 
24 –month SCr 
1998 N = 39 17 (43.6%*) 0 (0.0%) 0 (0.0%) 
1999 N = 55 49 (89.1%) 6 (10.9%) 4 (7.3%) 
2000 N = 53 41 (77.4%) 2 (3.8%) 2 (3.8%) 
2001 N = 61 48 (78.7%) 2 (3.3%) 1 (1.6%) 
2002 N = 67 48 (71.6.4%) 3 (4.5%) 1 (1.5%) 
2003 N = 58 51 (87.9%) 3 (5.2 %) 1 (1.7%) 
2004 N = 82 82 (100.0%) 7 (8.5%) 4 (4.9%) 
2005 N = 80 79 (98.8%) 7 (8.8%)  9 (11.3%) 
2006 N = 108 108 (100.0%) 6 (5.6%) 11 (10.2%) 
2007 N = 83 82 (98.8%) 10 (12.0%) 8 (9.6%) 
2008 N = 91 89 (97.8%) 61 (67.0%) 60 (65.9%) 
2009 N = 105 102 (97.1%) 73 (69.5%) 73 (69.5%) 
2010 N = 103 98 (95.1%) 70 (68.0%) 56 (54.4%) 
2011 N = 104 84 (80.8 %) 54 (64.3%) 62 (73.8%) 
2012 N = 63 62 (98.4%) 40 (64.3%) 50 (79.4%) 
2013 N = 72 72 (100.0%) 40 (63.5%) 48 (66.7%) 
2014 N = 41 41 (100.0%) 34 (82.9%)+ 2 (4.9%)+ 
Total Cohort 
(All Years) 
N = 1245 1,153 (92.6%) 439 (35.3%) 392 (31.4%) 
Source: 1998-2014 Indiana Network for Patient Care 
N = 1,245 
Notes: LKD(s) = living kidney donor(s); SCr = serum creatinine laboratory test 
*% Proportion of total living kidney donors with serum creatinine laboratory test at each time point in 
comparison to the total number of donors in that year 
+ Includes only LKDs with a donation date before May 2014 
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Table 4.2 Living Kidney Donor Follow-Up at 6-month, 12-month and 24-months: 
Urinalysis  
Donation  
Year 
Total LKDs 
in Year 
6 –month UA 
 
12 –month UA 
 
24 –month UA 
1998 N = 39 5 (12.8%*) 0 (0.0%) 0 (0.0%) 
1999 N = 55 7 (12.7%) 2 (3.6%) 3 (5.5%) 
2000 N = 53 12 (22.6%) 1 (1.9%) 1 (1.9%) 
2001 N = 61 16 (26.2%) 0 (0.0%) 0 (0.0%) 
2002 N = 67 11 (16.4%) 0 (0.0%) 0 (0.0%) 
2003 N = 58 11 (19.0%) 0 (0.0%) 1 (1.7%) 
2004 N = 82 14 (17.1%) 1 (1.2%) 1 (1.2%) 
2005 N = 80 14 (17.5%) 0 (0.0%)  5 (6.3%) 
2006 N = 108 20 (18.5%) 1 (0.9%) 1 (0.9%) 
2007 N = 83 7 (8.4%) 2 (2.4%) 1 (1.2%) 
2008 N = 91 6 (6.6%) 4 (4.4%) 4 (4.4%) 
2009 N = 105 14 (13.3%) 6 (5.7%) 7 (6.7%) 
2010 N = 103 12 (11.7%) 9 (8.7%) 7 (6.8%) 
2011 N = 104 10 (11.9%) 2 (2.4%) 3 (3.6%) 
2012 N = 63 5 (7.9%) 3 (4.8%) 4 (6.3%) 
2013 N = 72 11 (15.3%) 0 (0.0%) 2 (2.8%) 
2014 N = 41 3 (7.3%) 0 (0.0%)+ 0 (0.0%)+ 
Total Cohort 
(All Years) 
N = 1245 178 (14.3%) 31 (2.5%) 40 (3.1%) 
Source: 1998-2014 Indiana Network for Patient Care 
N = 1,245 
Notes: 
LKD(s) = living kidney donor(s); UA = urinalysis laboratory test to measure urine protein 
*% Proportion of total living kidney donors with urinalysis laboratory test at each time point in comparison 
to the total number of donors in that year  + Includes only LKDs with a donation date before May 2014 
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Table 4.3 Crude Age and Race Differences in 24-Month Follow-Up Kidney 
Laboratory Data in a Statewide Health Information Exchange 
Race SCr 24-Month  UA 24 –Month  
All Races % (OR) % (OR) 
   
Age 19-39 30% (0.84) 4% (1.84) 
Age 40-49 28% (0.82) 2% (0.49) 
Age 50-59 37% (1.33) 3% (0.91) 
Age 60+ 56% (2.86) 2% (0.71) 
Black or African-American   
   
Age 19-39 32% (0.33) 3% (0.22) 
Age 40-49 58% (2.48) 21% (9.07) 
Age 50-59 60% (2.45) 0% (0.00) 
Age 60+ -- -- 
Non-Black or African-American   
   
Age 19-39 30% (0.89) 4% (2.38) 
Age 40-49 27% (0.74) 1% (0.22) 
Age 50-59 36% (1.34) 3% (1.11) 
Age 60+ 58% (3.13) 3% (0.84) 
Source: 1998-2014 Indiana Network for Patient Care 
N = 1,245  
SCr = serum creatinine; UA = urinalysis  
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Table 4.4. Results of a Logistic Regression Model of 24-Month Follow-Up for Living 
Kidney Donors with Serum Creatinine Kidney Laboratory Data 
Variable Coefficient 
(βκ; log-odds) 
Standard 
error 
 
Odds 
Ratioa 
(OR) 
 
Lower 
95% 
CLc 
 
Upper 
95% 
CL 
 
Wald chi-
square 
 
p- valueb 
Age      13.971 0.003* 
(19-39)        
40-49 0.294 0.182 1.3 0.940 1.916 2.614 0.106 
50-59 0.584 0.199 1.8 1.213 2.652 8.586 0.003* 
60+ 1.090 0.398 3.0 1.363 6.489 7.502 0.006* 
Race        
(Non-black or 
African-
American) 
       
Black or 
African-
American 
0.685 0.278 2.0 1.150 3.418 6.073 0.014* 
Donor Era      248.079 0.000 
(1998-2004)        
2005-2008 
 2.220 0.309 9.2 5.022 16.879 51.538 0.000 
2009-2012 
 4.175 0.307 65.1 35.634 118.795 184.768 0.000 
2013-2014 3.098 0.344 22.2 11.284 43.481 81.035 0.000 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: N = 1,212 
Reference categories are in parentheses  
a. Odds ratio = elog-odds = eβ. Also known as relative odds.  
b. Test statistics and p-values pertain to both coefficients (log-odds) and odds ratios.  
c. CL = Confidence limit. The 95% confidence limits for the coefficient (log-odds) can be calculated as β± 
(1.96 x standard error). The confidence limits for the log odds ration are calculated e β± (1.96 x standard error)  
 
Based on SCr kidney laboratory data, LKDs between the ages of 40 – 49 had a 1.3 
times greater odds of having 24-month follow-up, while those aged 50 – 59 had 1.8 times 
greater odds as compared to 19-39 year olds. LKDs aged 60 or above at the time of 
donation had a three times the odds of having 24-month follow-up as compared to 
younger donors under 40. Donor era significantly contributed to the prediction. As 
compared to LKDs in the first donor era (1998-2004), those in the second data era (2005-
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2008) had 9.2 greater odds of receipt of 24-month follow-up. Those LKDs in the third 
donor era (2009-2012) had 65.1 times greater odds of 24-month follow-up than those 
who donated before 2004. Those LKDs in the fourth era (2013-2014) had 22.2 times 
greater odds than those donating between 1998 and 2004 to receive 24-month follow-up 
(p = 0.000). Black or African-American LKDs had about two times greater odds than 
those non-black or African-Americans to have 24-month follow-up (p = 0.014) based on 
SCr kidney laboratory data.  
For the assessment of 24-month follow-up based on UA kidney laboratory data, a 
test of the full model against a constant only model was statistically significant, 
indicating that the predictors as a set reliably distinguished between LKDs with UA 24-
month follow-up laboratory data (chi square = 18.132, p <0.042 with df = 7 Nagelkerke’s 
R2 = .060). Prediction success for the 24-month follow-up with UA laboratory data was 
96.8%. The Wald criterion demonstrated that age (p = 0.502) and race (p = 0.079) did not 
significantly contribute to the prediction, however, donation era was significant in this 
model (p =0.009). LKDs in the third data era (2009-2012) had four times greater odds of 
to having 24-month follow-up than those who donated in the first era (1998- 2004) as 
presented in Table 4.5.  
For sensitivity analysis of the donation era variable additional binomial logistic 
regression models were built to compare receipt of 24-month follow-up based on how the 
donation year variable was stratified. In the sensitivity analysis, models with three or four 
donation year categories dominated those with only two donation eras. As the odds and 
significance of age and race variables were robust in all models that stratified the 
donation year variable before and after the year 2004, a four-category donation era 
 
	
	
	
64 
specification was selected for the final model presented. Of note, there was a change in 
the impact of the oldest age group (age 60 and older) on receipt of 24-month follow-up 
when the specifications for the donation years were changed potentially reflecting a 
correlation between donation year and LKD age. 
Table 4.5. Results of a Logistic Regression Model of 24-Month Follow-Up for Living 
Kidney Donors with Urinalysis Kidney Laboratory Data 
Variable Coefficient 
(βκ; log-odds) 
Standard 
error 
 
Odds 
Ratio 
(OR)a 
 
Lower 
95% 
CLc 
 
Upper 
95% 
CL 
 
Wald 
chi-
square 
 
p- valueb 
Age       2.357 0.502 
(19-39)        
40-49 -0.654 0.439 0.52 0.220 1.228 2.225 0.136 
50-59 -0.205 0.443 0.82 0.342 1.940 0.215 0.643 
60+ -.0516 1.044 0.60 0.077 4.615 0.245 0.621 
Race        
(Non-black or 
African-
American) 
       
Black or 
African-
American 
0.822 0.469 2.3 0.908 5.699 3.079 0.079 
Donor Era      11.498 0.009* 
(1998-2004)        
2005-2008 
 0.537 0.525 1.7 0.612 4.786 1.049 0.306 
2009-2012 
 1.377 0.471 4.0 1.574 9.980 8.543 0.003* 
2013-2014 0.155 0.828 1.2 0.231 5.916 0.035 0.851 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: N = 1,212 
Reference categories are in parentheses  
a. Odds ratio = elog-odds = eβ. Also known as relative odds.  
b. Test statistics and p-values pertain to both coefficients (log-odds) and odds ratios.  
c. CL = Confidence limit. The 95% confidence limits for the coefficient (log-odds) can be calculated as β± 
(1.96 x standard error). The confidence limits for the log odds ration are calculated e β± (1.96 x standard error) 
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Discussion 
Binomial logistic regression models show that LKD age at time of donation is 
significantly associated with receipt of 24-month follow-up. With respect to age, younger 
donors (under the age of 40) have lower odds of having 24-month SCr follow-up kidney 
laboratory data, a clinical value used to measure renal function compared to older donors. 
Black or African-American LKDs have two times greater odds as non-Black or African-
Americans to have received 24-month follow-up. Donation era was a significant predictor 
of receipt of 24-month follow-up based on SCr and UA kidney laboratory data as LKDs, 
with donation dates before 2004 having lower odds of having 24-month follow up than 
those who donated after 2004. Follow-up at 24-months significantly improved between 
2005 and 2008 and again between 2009 and 2012. Donors in the fourth donation era 
(2013 and 2014) had about 22 times greater odds than for those who donated between 
1998 and 2004 to have 24-month follow-up. Findings suggest that LKD follow-up has 
improved over time and changes in OPTN policy have led to an improvement in 24-
month follow-up. The proportion of LKDs within each donation year with timely and 
complete 24-month follow-up has increased over time and is reflected in this transplant-
center level cohort. Furthermore, these findings suggests and reflects that participation in 
the collection and reporting of patient data to INPC has evolved over time, and especially 
since improvements to the technical operation of the statewide HIE were implemented by 
the end of 2004.  
Follow-up care is important for continued patient safety in live donation, as well 
as for transplant center compliance with OPTN/UNOS policy (OPTN, 2016e). This study 
provides additional evidence of what has been previously described by Schold et al. 
 
	
	
	
66 
(2012) regarding LKD follow-up including associations of age and the capture of post-
donation follow-up data (J. D. Schold et al., 2012). With data from the Scientific Registry 
for Transplant Recipients, the presence of follow-up data was recently shown to be highly 
variable by individual transplant center, with only 30 - 40% of known variation in 
missing data explained at the transplant center level (J. Schold et al., 2015). In this same 
national study, differences in complete follow-up were most dramatic by donor age, race, 
educational attainment, distance between donors’ residence, and the transplant center, 
and size of the living donor program (J. Schold et al., 2015). Other previous studies 
described missing follow-up data to be associated with characteristics that increase LKD 
risk for future medical problems including the development of chronic conditions such as 
diabetes and hypertension (Lentine & Patel, 2012). Incomplete follow-up may reflect 
both patient and transplant center factors, including variable infrastructure and processes 
in which follow-up care is provided (D. A. Mandelbrot et al., 2009; J. Schold et al., 
2015). Previous studies have shown missing follow-up data to be correlated with LKDs 
residing longer distances from the transplant center for which the donation took place (J. 
Schold et al., 2015).  
 Knowledge of age and racial differences in complete and timely follow-up care 
for LKDs explored in this study provides valuable information for transplant centers and 
research teams recognizing the need to develop new behavioral and technological 
interventions to improve follow-up care. Transplant centers can use knowledge of current 
follow-up care patterns in the planning and development of implementation strategies 
designed to improve follow-up care processes at the administrative and regulatory 
compliance level. As such, evidence that younger LKDs are less likely to have timely and 
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complete post-donation follow-up can help transplant centers in the creation of patient-
centered messages that reinforce that follow-up care is essential for donor safety, clinical 
care, and improved informed consent. 
There are several limitations to this study that deserve mention. While LKDs with 
a donation year in 2013 and 2014 were included for analyses, not all donors from these 
years have 24-month follow-up laboratory data available in INPC based on the date of 
our data query and our inability to capture LKDs past May of 2014 (See Chapter 3). 
Importantly, the presence or absence of LKD follow-up kidney laboratory data does not 
necessarily mean that follow-up care did or did not occur. Our study uses the policy 
language of ‘timely and complete’ in deeming kidney laboratory data as a proxy for 
receipt of 24-month follow-up. LKDs who may have received follow-up that occurred 
outside of the 60-day window after the 24-month anniversary of the donation date were 
not included in this analysis. Analysis of 24-month follow-up is limited by the data 
source, meaning that a donor must have received follow-up from an institution 
participating in INPC. As INPC is primarily a statewide clinical data source, it may not 
capture data on LKDs who left the state and received follow-up care. Finally, there is the 
possibility that kidney-specific labs were performed, but were not subsequently reported 
to the transplant center. While this is not a significant limitation to our understanding of 
receipt of 24-month follow-up in this analysis, routine UA laboratory data was limited in 
INPC in comparison to SCr laboratory data in this study (See Table 4.1 and Table 4.2). 
Routine UA results are further difficult to clinically quantify and discern (i.e. trace, 
positive, negative) results are documented in INPC. There may be other reasons at the 
institutional level, such as that some routine results are not sent to INPC due to 
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administrative burden or cost. It is recommended that the usability and utility of a post-
donation UA to improve understanding of live donor risk as supported by the current 
OPTN/UNOS Living Donor Follow-Up Worksheet (Appendix C) and affiliated 
regulations, be critically re-examined in future studies. Some the time, both albumin and 
creatinine are measured in a random urine sample and an albumin/creatinine ratio (ACR) 
is calculated to more accurately assess kidney function. An ACR may be done to more 
accurately determine how much albumin is escaping from the kidneys into the urine. This 
study did not assess ACR.  
Conclusion  
This is the first study to examine LKD follow-up at Indiana University Health and 
reinforces the idea that the capacity to acquire LKD follow-up is affected in part by 
structures and processes within a health care system. This study provides previously 
unknown information about historical trends and differences in LKD follow-up care by 
age and race, where the most significant differences on receipt of 24-month follow-up 
was age. This knowledge of age-related differences in LKD follow-up care patterns at the 
transplant center level can assist research teams in the design and development of 
interventions to improve care and patient outcomes. New population health management 
tools for LKDs could include administrative and managerial dashboards at the transplant 
center level. At the patient level, web-based or mobile applications or text messaging 
could be used to facilitate and sustain communication with younger donors who may be 
less likely to access the follow-up care. 
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INPC data demonstrates the ability to capture 24-month follow-up SCr and UA 
kidney laboratory data. Thus, a statewide HIE, such as demonstrated by INPC, can serve 
as a catalyst for connecting all hospitals and physicians in a single community, region or 
state, to provide LKD follow-up data. Further research on access to existing data sources 
including other existing statewide HIE infrastructures could improve follow-up reporting 
and compliance as required by OPTN/UNOS for other transplant centers. The transplant 
community at large may benefit from examining HIE as a new clinical data source for 
integrating existing data to improve follow-up care for all living donors.  
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CHAPTER FIVE: FOLLOW-UP HEALTH OUTCOMES OF LIVING KIDNEY 
DONORS IN A HEALTH INFORMATION EXCHANGE: RENAL FUNCTION, 
DIABETES MELLITUS AND HYPERTENSION  
Abstract 
Objective: To evaluate the 24-month follow-up health outcomes in living kidney donors 
(LKDs) including renal function and differences by age, race, and sex as well as 
incidence of (DM) and hypertension (HTN).  
Design: A retrospective cohort study using data from the Indiana Network for Patient 
Care (INPC).  
Participants: Medical records of 392 LKDs aged 19 - 66 years old who donated a kidney 
between 1999 and 2014.  
Methods: Predictors of LKD 24-month renal function including age, race and sex were 
assessed by linear regression with inclusion of two-way interaction to test for effect 
modification. Renal function was measured by estimated glomerular filtration rate 
(eGFR) and was calculated from the mean 24-month follow-up serum creatinine (SCr) 
measurement using the CKD-EPI equation. Incidence rates of diabetes mellitus (DM) and 
hypertension (HTN) were identified by administrative diagnosis codes using the 
International Classification of Disease Modification Ninth Revision Clinical Modification 
(ICD-9-CM).  
Results: Median (IQR) eGFR was 64.8 (18.1) ml/min/1.73m2. In the adjusted multiple 
linear regression model, Black or African-American LKDs had lower follow-up eGFR at 
24-months  (-7.0 mL/min/1.73m2; p=0.008) than those non-Black or African-American. 
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Male LKDs had lower eGFR (-48.5 mL/min/1.73m2; p = 0.000) than females. When 
interactions were introduced into the model, the association was amplified in younger 
donors and attenuated in older donors (0.34 mL/min/1.73m2; p = 0.017). One donor had a 
diagnosis of DM, while three had a HTN diagnosis between one day and ≥24-months 
post-donation.  
Conclusions: Post-donation renal function is lower in male and Black or African-
American LKDs than females, particularly among younger donors.  
Keywords: health information exchange; living kidney donors; chronic diseases; 
diabetes; hypertension 
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Introduction 
Follow-up for living kidney donors (LKDs) in the first 24-months (or two-years) 
following donation are important processes of care in order to monitor post-surgical 
complications, to ensure patient safety, and to provide informed consent for future donor 
candidates. Since 2013, during the 24-month follow-up period mandated by the Organ 
Procurement and Transplantation Network (OPTN), transplant centers are required to 
report health outcomes of interest including renal function via kidney laboratory data, and 
the development of diabetes mellitus (DM) and hypertension (HTN) from laboratory data 
collected on the LKD. (OPTN, 2016b). As part of OPTN informed consent policy, 
candidates undergoing evaluation must be informed that they may have a 25-35% 
permanent loss in kidney function after donation (OPTN, 2016b). This is because kidney 
donation can lead to a loss of approximately 50% of nephron mass, with an immediate 
and corresponding decrease in renal function; however, the remaining healthy renal 
parenchyma has the ability to recover a significant percentage of lost function within a 
relatively short time (Srinivas & Poggio, 2012). As a measure of renal function, a 
glomerular filtration rate (GFR) can be calculated from serum creatinine (SCr) based 
formulas. Furthermore, an estimated glomerular filtration rate (eGFR) measurement is a 
closer estimate of true GFR than serum creatinine alone and is recommended for use in 
clinical practice by many authorities (A. S. Levey et al., 1999; A. S. Levey et al., 2003; 
A. S. Levey et al., 2005).  
 Kidney Disease Improving Global Outcomes (KDIGO) calls CKD a global 
public health problem, and there are approximately 13% of American adults with the 
disease (Coresh et al., 2007; Drey, Roderick, Mullee, & Rogerson, 2003; A. Levey et al., 
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2007; A. S. Levey & Coresh, 2012; A. S. Levey et al., 2011). As shown in Table 5.1, in 
Stage 1, renal function remains normal and then becomes minimally reduced in Stage 2. 
According to the National Institute of Diabetes, Digestive and Kidney Diseases, a GFR of 
60 mL/min per 1.73 m2 or higher is the normal range, while numbers below 60 may 
indicate CKD. Pre-donation GFR values exceeding 80 mL/min per 1.73 m2 are usually 
considered suitable for living kidney donation, but guidelines are not specific the method 
on how GFR should be calculated (OPTN, 2016c). Nevertheless, no standardized 
reference values exist for many of the procedures used to assess renal function used in 
clinical practice and thus, the decision of proceeding (or not) with donation is 
unfortunately often a matter of subjective interpretation rather than more precise 
science.(Srinivas & Poggio, 2012). As there is a significant emphasis placed by the NKF 
on GFR to determine the state of renal health versus disease, renal function assumes an 
even greater role in understanding living donor outcomes (A. S. Levey et al., 2003). 
 
Table 5.1 The Five Stages of Chronic Kidney Disease  
Stage Qualitative Description GFR 
1 Normal or high GFR > 90 mL/min 
2 Mild CKD 60-89 mL/min 
3A Moderate CKD 45-59 mL/min 
3B Moderate CKD 30-44 mL/min 
4 Severe CKD 15-29 mL/min 
5 ESRD <15 mL/min 
Source: The National Kidney Foundation 
GFR = glomerular filtration rate, CKD = chronic kidney disease 
Normal GFR results range from 90 - 120 mL/min/1.73 m2 
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Most people will not know they have Stage 1 CKD, unless discovered during 
screening for another condition, including testing for DM and HTN. As two of the 
leading causes of CKD, DM and HTN historically have been contraindications to living 
kidney donation and exclude a candidate early in the evaluation and screening phase 
(Chen et al., 2004; Pyram, Kansara, Banerji, & Loney-Hutchinson, 2012). Although few 
transplant centers will approve LKD candidates with impaired glucose tolerance, most, if 
not all, have historically denied candidates with a diagnosis of DM (Bia et al., 1995; D. 
Mandelbrot et al., 2007; Vigneault, Asch, Dahl, & Bia, 2011). Currently, OPTN policy 
lists DM as absolute exclusion criteria for living kidney donation (OPTN, 2016c). 
Although the clinical definition of HTN has changed over time with different levels of 
acceptable diagnosis and treatment thresholds (Carretero & Oparil, 2000) individuals 
diagnosed and untreated have commonly been excluded from donating a kidney in the 
past on the basis that nephrectomy may increase blood pressure (Ierino, Boudville, & 
Kanellis, 2010).  
Addressing follow-up clinical outcomes in LKDs including those of DM and 
HTN is becoming easier as new clinical data sources such as health information exchange 
(HIE) have increasingly captured follow-up kidney laboratory data. There is now an 
opportunity to improve knowledge about follow-up health outcomes for this newly 
identified cohort of LKDs. The objective of this study is to examine follow-up health 
outcomes including renal function and differences in age, race and sex, and to describe 
the incidence of DM and HTN in a cohort of LKDs at 24-months post-donation follow-
up.  
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Methods 
Data Source 
The Indiana Network for Patient Care (INPC) is the database of clinical and other 
information that is available though the Indiana Health Information Exchange.  Derived 
from a variety of Electronic Health Record (EHR) systems, INPC represents one of the 
largest patient networks in the country (Biondich & Grannis, 2004). Over 100 separate 
healthcare entities provide data to INPC including: major hospitals, health networks, and 
insurance providers. INPC also includes outpatient data from participating physician 
offices, community health and indigent care centers, county and state public health 
departments, national laboratories, payers and ancillary sources such as radiology 
systems (Biondich & Grannis, 2004; McDonald et al., 2005). When combined, the 
information from these institutions represent data on over 17 million patients in the form 
of 4.9 billion clinical observations, 951 million encounter records and over 195 million 
multimedia reports (Institute, 2015).  
 
Participants 
Three hundred ninety-two LKDs (N = 392) who donated a kidney between 
January 1999 and May 2014 at Indiana University Health who received follow-up care at 
24-months post-donation, make up the sample population for this study (See Chapters 3 - 
4). All LKDs in this study are believed to have timely and complete follow-up as 
measured by the ±60 days of the 24-month anniversary of the donation date.  
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Outcome Measures 
Appendix D contains a detailed supplemental literature review about the selected 
outcome and predictor variables used in previous studies of LKDs.  
Renal function measured by (eGFR) was calculated from the serum creatinine 
(SCr) value reported  ±60 days of the 24-month anniversary of the donation date using 
the CKD-EPI equation: GFR = 141 * min(SCr/κ,1)α * max(SCr/κ, 1)-1.209 * 0.993Age * 
1.018 [if female] * 1.159 [if black]. SCr is serum creatinine (mg/dL), κ is 0.7 for females 
and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the 
minimum of SCr/κ or 1, and max indicates the maximum of SCr/κ or 1. If there were 
multiple 24-month SCr values in INPC for the donor, the mean was used. The CKD-EPI 
equation calculates eGFR based on sex as a binary variable (Male or Female), race as a 
binary variable (Not Black or African-American, or Black or African-American), current 
age in years as a continuous variable, and SCr in mg/dL (Florkowski & Chew-Harris, 
2011). Note: The race variable used for eGFR was computed where non-Black or 
African-American included Asian, Native American Pacific Islander, or White LKDs. If 
race was classified in INPC as ‘null or code not mapped’ and ‘other or unknown’ the 
LKD was treated as missing data and were therefore was not included in analysis of 
eGFR.  
Diabetes mellitus (DM): Diagnosis of DM was determined based on International 
Classification of Disease Ninth Revision Clinical Modification (ICD-9-CM) code 250 or 
an internal diagnosis code (DM, non- insulin dependent, DM uncontrolled, diabetes out 
of control, diabetic, DM) used by the healthcare provider or system and accessible within 
INPC to the experienced data analyst at Regenstrief Institute. DM diagnosis was 
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classified if the diagnosis code appeared in INPC ≥ one day but within ≤ 790 days (24-
months after the kidney donation ±60 days).  
Hypertension (HTN): Diagnosis of HTN was based on ICD-9-CM codes 
including 401.0 malignant essential HTN, 401.1 benign essential HTN, 401.9 unspecified 
essential HTN, 405.01, malignant renovascular HTN, 405.09, other malignant secondary 
HTN, 405.11, benign renovascular HTN, 405.19 other benign secondary HTN, 405.91 
unspecified renovascular HTN, and 405.99 other unspecified secondary HTN. HTN 
diagnosis was determined if the diagnosis code appeared in INPC ≥ one day but within ≤ 
790 days (24-months after the kidney donation ±60 days).  
Independent Variables 
Age at time of donation has a normal distribution and was treated as a continuous 
variable.  
Race was treated a binary categorical variable classified as non-black or African-
American (0) and Black, African-American (1).  
Sex was a binary variable and defined as female (0) and male (1).  
Note: The race variable used for eGFR was computed where non-Black or African-
American included those with races in INPC classified as Asian, Native American Pacific 
Islander, or White. If race was classified in INPC as ‘null or code not mapped’ and ‘other 
or unknown’ the subject was treated as missing data and were therefore not included in 
analysis of eGFR.  
Statistical Analysis 
Predictors of follow-up eGFR at 24-months including age, race and sex were 
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assessed with multiple linear regression and the inclusion of two-way interaction to test 
for effect modification. Incidence proportion and rate for new cases of post-donation DM 
and HTN at 24-month donation anniversary (+ 60 days) was calculated. All analyses and 
descriptive statistics were carried out with SPSS, version 23 (IBM SPSS Statistics, Inc.) 
with a 95% confidence level where p (<0.05) is considered significant.  
Results 
Of 392 LKDs that received follow-up at 24-months, the median interquartile 
range (IQR) age at time of donation was 41 years old (33-51). Two hundred and thirty-
two (61.7%) LKDs were female and 150 (38.3%) were male. Thirty-six (9.2%) LKDs 
were Black or African-American. For analysis of follow-up renal function at 24-months 
(eGFR CKD-EPI), there were 386 LKDs included. Follow-up renal function at 24-
months by LKD baseline demographic characteristics are presented in Table 5.2 (Note: 
baseline demographics as presented in tabular form show age as a categorical variable; 
age was used as a continuous variable in all reported analyses). The median age at time 
of donation was 40.4 years. Median 24-month post-donation eGFR was 62.8, while the 
mean eGFR was 64.8 (S.D.=15.5, 95% CI 63.2 - 66.3) mL/min/1.73m2.  
The multiple linear regression model presented in Table 5.3 accounted for 61.7% 
of the variance in eGFR, F (4,381) = 155.82, p < 0.000. Sex makes the strongest 
contribution to explaining the dependent variable eGFR (p = 0.000). In the adjusted 
model, Black or African-American LKDs had lower post-donation eGFR (-7.0 
mL/min/1.73m2; p=0.008) than those non-Black or African-American. Male LKDs had 
lower eGFR (-48.5 mL/min/1.73m2; p = 0.000) than females at 24-month follow-up. 
When interactions were introduced into the model, the association of moderating 
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variables age and sex was amplified in younger donors and attenuated in older donors 
(0.34 mL/min/1.73m2; p = 0.017).  
The incidence proportion of DM at 24-months is one in 392, and for HTN is three 
in 392; the incidence rates are 0.25% and 0.77% respectively. With such few disease 
outcomes, further and additional inferential statistical analysis could not be reported for 
this study.  
Table 5.2 Non-Adjusted Post-Donation Living Kidney Donor Renal Function at 24-
Months by Baseline Donor Demographics 
 Median 
eGFRa 
Mean  
eGFR 
Standard 
Deviation  
Lower 
CL 95% 
Upper 
CL 95% 
Age Category      
19-39 
 
88.9 93.5 25.4 89.7 97.3 
40-49 
 
84.9 83.4 21.4 79.2 87.6 
50-59 
 
68.1 70.7 19.6 66.5 74.9 
60+ 
 
79.5 75.6 17.0 68.3 82.9 
Race      
Non-Black 
African-
American 
 
83.3 85.3 24.5 82.7 87.9 
Black or 
African-
American 
80.3 78.7 23.8 70.7 86.7 
 
 
 
Sex      
Male 92.9 96.8 21.3 94.1 99.5 
Female 64.7 65.2 14.5 62.8 67.5 
Source: 1999-2014 Indiana Network for Patient Care 
Notes: N = 386 
a. eGFR = Estimated Glomerular Filtration Rate is expressed as mL/min/1.73m2 as calculated by CKD-EPI 
equation where expressed as a single equation, is: GFR = 141 * min(SCr/κ,1)α * max(SCr/κ, 1)-1.209 * 
0.993Age * 1.018 [if female] * 1.159 [if black] where SCr is serum creatinine (mg/dL), κ is 0.7 for females 
and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of SCr/κ or 1, 
and max indicates the maximum of SCr/κ or 1.  
CL = Confidence limit. The 95% confidence limits are calculated as β± (1.96 x standard error) 
 
 
 
83	
	
	
	
Table 5.3 Results of Linear Regression of Post-Donation Renal Function at 24-
Months by Age, Race, and Sex, Living Kidney Donors 
Variable Coefficient  
(βκ) 
Standard 
error t-statistic P-value 
 
Lower 
95% CL 
 
Upper 
95% CL 
Age  -1.14b 0.09 -13.12 0.000* -1.31 -0.97 
Race -7.04 2.66 -2.65 0.008* -12.3 -1.8 
Sex -48.53 6.39 -7.59 0.000* -61.1 -35.95 
Age/Sex 
Interaction 0.34 0.14 2.60 0.017* 0.062 0.624 
Source: 1999-2014 Indiana Network for Patient Care 
Notes: N = 386 F-Statistic is 155.822 with 4 df; adjusted R2 = 0.617  
Coefficients are for Estimated Glomerular Filtration Rate (eGFR) and presented as unstandardized  
CL = Confidence limit. The 95% confidence limits are calculated as β± (1.96 x standard error), with a         
P-value <0.05 considered to be significant* 
 
Discussion 
The goal of the present study was to understand differences in post-donation 
eGFR and the incidence of DM and HTN at the time of 24-month follow-up in a newly 
identified retrospective cohort of LKDs. Results of an adjusted linear regression model 
shows that eGFR was lower in black and male LKDs with the association amplified in 
younger donors at the 24-month follow-up. Age is a known natural predictor of renal 
function decline in health adults (Epstein, 1996; Lindeman, Tobin, & Shock, 1985; 
Lindeman, Tobin, & Shock, 1984). In LKDs, renal function of the remaining kidney is 
expected to improve for many years, but will show signs of slight deterioration long-term 
(>15 years) (Fehrman-Ekholm et al., 2011). The identification of the risk of post- 
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donation renal decline resulting in CKD is limited to the first year post-donation in most 
studies; However, previous studies have clearly shown that a variable fraction of LKDs 
will have eGFR values <60 mL/min/1.73 m2 and that the risk of such post-donation CKD 
varies with age at time of donation, baseline eGFR, and demographics such as sex and 
race (Barri, Parker Iii, Kaplan, & Glassock, 2009; A. Garg et al., 2006; Najarian, 
McHugh, Matas, & Chavers, 1992; Parasuraman & Venkat, 2008; Poggio et al., 2009; 
Wan, Spalding, Winch, Brown, & Geddes, 2007). The unadjusted median eGFR 
measurements for our cohort ranged from 68.1 mL/min/1.73 m2 to 88.9 mL/min/1.73 m2. 
These results are consistent with what is disclosed in in the OPTN/UNOS informed 
consent process, and places the LKDs in this cohort within the CKD spectrum as outlined 
by the National Kidney Foundation.   
Renal diseases typically begin in middle age and take decades to progress to from 
CKD to ESRD at a median age of 64, therefore, existing 10-15 year studies will not 
capture the lifetime risks of post-donation ESRD (Grams, Chow, Segev, & Coresh, 
2013). Most renal diseases will cause lesser decreases in renal function beginning in 
middle age, while the prevalence of a GFR<30 mL/min/1.73 m2 increases sevenfold from 
ages 40 to 50, and increases again almost threefold to about 1% of the population by age 
60 (Grams et al., 2013; Hoerger et al., 2010). Therefore, while ESRD was not assessed in 
this study, data shows that younger LKDs are at demonstrably higher risk than older 
candidates for developing ESRD (Steiner, 2014) as there is only a 2-3% lifetime risk for 
ESRD that manifests from ages 30-40, while at age 60 more than half the lifetime risk for 
ESRD remains (Narayan, Boyle, Thompson, Sorensen, & Williamson, 2003). Therefore, 
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the progression of CKD to ESRD in LKDs is a valid concern in the transplant 
community.  
New research assessing the incidence of HTN and DM in a national cohort of 
LKDs found that the risk of ESRD secondary to diabetes and hypertension was low in 
early years post-donation and increased substantially over time (Anjum et al., 2016). The 
development of a chronic condition post-donation such as DM and HTN would put an 
LKD at increased risk for CKD and ESRD. As with all else equal, if kidney donation 
sacrificed 40 mL/min/1.73 m2, because of the development of post-donation diabetic 
nephropathy or other diseases that lost an additional 40 mL/min/1.73 m2 per decade, an 
individual would reach ESRD ten years earlier because of donation (Keith, Nichols, 
Gullion, Brown, & Smith, 2004; Steiner, Ix, Rifkin, & Gert, 2014).  
In this current study, one LKD developed DM and three (0.07%) developed HTN 
by the time of 24-month follow-up. In a systematic review of the literature from 1966 to 
2006, Young et al. noted that living donors studied up to 11 years post-donation seldom 
develop the metabolic, endocrine, hematology or micro-inflammatory disturbances 
commonly associated with established CKD caused by parenchymal renal disease leading 
to ESRD (Young et al., 2007). However, according to the United States Renal Data 
Service, Type 2 DM causes almost all acquired, adult onset ESRD, with an overall 
lifetime risk of self-reported diabetes risk of 33% in men and 39% in women that is 
increased to about 50% for Hispanic and Black or African-American women (Narayan et 
al., 2003). This is increasingly important with new targeted educational interventions for 
minority populations (Gordon et al., 2015), as well as several other interventions 
designed with the goal of educating transplant centers and patients on strategies that can 
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be implemented to assist in reducing disincentives for transplant candidates in seeking 
living donation  (Boulware et al., 2011; Patzer et al., 2015; J. Rodrigue, Cornell, Lin, 
Kaplan, & Howard, 2007; J. R. Rodrigue et al., 2015; Amy D Waterman et al., 2015).  
While Type 2 DM is not common in individuals under 30 years old, current 
protocols used by transplant centers to screen and exclude living donor candidates have 
not reduced the risk of post-donation diabetes (Boyarsky BJ, 2012; H. N. Ibrahim et al., 
2009; Lentine et al., 2010). There are a number of older studies that report incidence rates 
of HTN following kidney donation at various follow-up points, ranging between 9% and 
48% (Anderson et al., 1985; Dunn et al., 1986; Fehrman-Ekholm et al., 2011; Hakim, 
Goldszer, & Brenner, 1984; Miller et al., 1985; Talseth et al., 1986; Tapson et al., 1985; 
Torres et al., 1987; Warnick, Jenkins, Baumgarten, & Bia, 1988). Another study showed 
that Black or African-American race is associated with an increased risk for the 
development of post-donation HTN as compared to white donors (Doshi, Goggins, Li, & 
Garg, 2013; Lentine et al., 2010). Assessing risk for HTN attributable to kidney donation 
has been challenging and very few studies have done such that would be included for 
evidence in clinical guideline development (See Appendix D). A more recent 
retrospective matched-control cohort of 1,200 LKDs assessing post-donation HTN with a 
mean follow-up of 6.4 years, found that LKDs had a 40% increased risk (hazard ratio, 
1.4; CI, 1.2–1.7) of being diagnosed with HTN compared with that of non-donor controls 
(A. X. Garg et al., 2008). In another study, HTN increased from 14% in the early post-
donation period to 57% in the late post-donation period, however, the sample size was 
small (n=21) and the extent to which incident HTN is attributable to kidney donation is 
difficult to judge (Lenihan et al., 2015). While this study did not assess blood pressure, 
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recently a prospective study of LKDs and matched healthy controls found no difference 
in blood pressure between LKDs and controls observed for the first three years after 
donation (Kasiske et al., 2015).  
There are several limitations to this study that deserve mention. First, we are only 
assessing outcomes for LKDs that are known to have received follow-up care at 24-
months post-donation based on kidney laboratory data (See Chapter 4). We do not have 
mortality data on these LKDs to date in INPC. Additionally, analysis of renal function 
with eGFR (CKD-EPI) is acceptable in CKD epidemiology and clinically; however there 
is the possibility that different calculations for eGFR such as the Modification of Diet in 
Renal Disease Study would provide different results (Matsushita et al., 2012). 
Assessment of pre and post-donation renal function are critical aspects of the evaluation 
and follow-up care process, and the obtained information should always be interpreted in 
the context of other clinical and laboratory data were not assessed in this study. We used 
the threshold of +60 days from the 24-month donation anniversary to assess incidence of 
DM and HTN, which were identified only by ICD-9-CM codes captured within INPC. 
Therefore, there could be LKDs who received follow-up care at 24-months in our sample 
who developed DM or HTN, but a diagnosis was not captured by INPC. Due to such few 
DM and HTN outcomes at 24-months post-donation, inferential analyses would result in 
insignificant findings and reporting these cases could compromise patient confidentiality. 
The present study begins to advance the state of knowledge about health 
outcomes in a cohort of LKDs from Indiana University Health, including renal function 
measured as eGFR and the development the chronic conditions DM and HTN during the 
24-month follow-up period currently mandated by the OPTN. At the transplant center 
88	
	
	
	
level, this knowledge can be used to support LKD candidate education, screening, and 
informed consent.  
Conclusion 
Follow-up health outcomes from this cohort of LKDs identified in a statewide 
HIE demonstrate that 24-month renal function is lower in male and black or African-
American LKDs. Only one donor developed DM and three developed HTN by 24-month 
follow-up. Knowledge of follow-up health outcomes in this cohort can be useful at the 
transplant center level and to the larger scientific community in better understanding and 
promoting improved informed consent for living donation based on the most current 
CKD epidemiology. Future research should evaluate these findings in larger samples of 
LKDs in order to assess risk of DM and HTN attributable to living kidney donation. 
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CHAPTER SIX: CONCLUSIONS AND FUTURE RESEARCH  
 Follow-up care is critical for understanding health outcomes of LKDs, but 
historically many have been lost-to-follow-up in the months and years following 
donation. This chapter addresses how each study in this dissertation makes a scientific 
contribution to our better understanding of living donor health outcomes and provides 
practice and policy implications and future research steps.  
The transplant community has now recognized that despite past and current 
efforts to increase registrations for organ donation, the number of deceased donors will 
never be sufficient (Goldberg, French, Abt, & Gilroy, 2015). Living donor kidney 
transplants have better graft survival rates than transplants with deceased donor kidneys, 
significantly reduce the national waiting list, allow for incompatible kidney paired 
donation, and allow preemptive renal transplantation prior to dialysis for end-stage renal 
disease (ESRD) (Matas et al., 2015; A. D. Waterman et al., 2015). Patient safety remains 
at the foundation of clinical and ethical discussions regarding the practice of living 
donation.  
 
Clinical Informatics to Identify Living Kidney Donors in Novel Clinical Data Sources 
In this dissertation, a novel method for identifying LKDs in a statewide Health 
Information Exchange (HIE) was applied using a novel text-mining approach and tools of 
clinical informatics including natural language processing (See Chapter 3). To our 
knowledge, this study is the first of its kind to identify LKDs in HIE. The LKD cohort 
identified showed high correlation with Organ Procurement and Transplantation Network 
LKD frequency by year (r = 0.948), demonstrating that the methodology was effective 
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for our sample population. As HIE efforts expand across the nation, these repositories are 
valuable sources that be further explored for use in clinical and research scenarios to 
improve follow-up and involving patients who span many care providers. The 
introduction of new big data sources like HIE which have the capacity to capture 
laboratory data over time may very well contribute to our knowledge of live donor 
outcomes. This dissertation demonstrated that the tools of clinical informatics assist in 
identifying and to study follow-up outcomes of living kidney donors (LKDS) in novel 
clinical data sources.  
 
Big Data and Statewide Health Information Exchange to Evaluate Living Kidney Donor 
Follow-Up Care Patterns 
Transplant centers must submit living donor follow-up data for two-years (24-
months) from the anniversary of the kidney donation. As explored in Chapter 4 of this 
dissertation, the Indiana HIE demonstrates the capacity to capture follow-up kidney 
laboratory data on the cohort of identified LKDs. LKDs between the ages of 40 – 49 have 
are 1.3 times more likely of having 24-month follow-up, while those aged 50 – 59 are 1.8 
times more likely as compared to 19-39 year olds. LKDs in the third donor era (2009-
2012) were 65.1 times more likely to have 24-month follow-up than those who donated 
before 2004 while those LKDs in the fourth era (2013-2014) were 22.2 times more likely 
than those donating between 1998 and 2004 to receive 24-month follow-up (p = 0.000). 
Black or African-American LKDs were about twice as likely than those non-black or 
African-Americans to have 24-month follow-up (p = 0.014).  
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This study shows that while 24-month follow-up has improved over time, younger 
LKDs under 40 may be less likely to get follow-up care than those in older age 
categories. In addition to differences in receipt of follow-up care by age and other 
predictors; follow-up care patterns reflect the development of new policy by the Organ 
Procurement and Transplantation Network/United Network for Organ Sharing 
(OPTN/UNOS) Living Donor Committee extending follow-up requirements.  
 
Examining Health Outcomes of Living Kidney Donors in a Health Information Exchange  
In this study the 24-month follow-up health outcomes in living kidney donors 
(LKDs) including renal function and differences by age, race, and sex as well as 
incidence of (DM) and hypertension (HTN) were evaluated. Predictors of LKD 24-month 
renal function including age, race and sex were assessed by linear regression with 
inclusion of two-way interaction to test for effect modification. Renal function was 
measured by estimated glomerular filtration rate (eGFR) and was calculated from the 
mean 24-month follow-up serum creatinine (SCr) measurement using the CKD-EPI 
equation. Incidence rates of diabetes mellitus (DM) and hypertension (HTN) were 
identified by administrative diagnosis codes using the International Classification of 
Disease Modification Ninth Revision Clinical Modification (ICD-9-CM).  
Median (IQR) eGFR was 64.8 (18.1) ml/min/1.73m2. In the adjusted multiple 
linear regression model, Black or African-American LKDs had lower follow-up eGFR at 
24-months    (-7.0 mL/min/1.73m2; p=0.008) than those non-Black or African-American. 
Male LKDs had lower eGFR (-48.5 mL/min/1.73m2; p = 0.017) than females. When 
interactions were introduced into the model, the association was amplified in younger 
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donors and attenuated in older donors (0.34 mL/min/1.73m2; p = 0.017). One donor had a 
diagnosis of DM, while three had a HTN diagnosis between one day and ≥24-months 
post-donation. Post-donation renal function is lower in male and Black or African-
American LKDs than females, particularly among younger donors.  
While this study only assessed LKD outcomes at 24-month follow-up, there 
should be no controversy that a continued commitment to increasing knowledge about 
long-term health outcomes (>2 years; See Chapter 2, Henderson Conceptual Model for 
Living Kidney Donor Follow-up) is essential to ensure patient safety in living kidney 
donation. This is particularly true as new-onset morbidity including the development of 
diabetes and hypertension takes years to emerge, making it highly likely that they will be 
missed during the 24-month (two-year) follow-up period currently mandated by OPTN, 
the United Network for Organ Sharing (UNOS), and the Centers for Medicare and 
Medicaid Services. It is known that kidney function declines with time, and there are data 
showing a minority of LKDs progressing to chronic kidney disease (CKD), with some 
even requiring dialysis (Gibney, Parikh, & Garg, 2008; Klop et al., 2015; Nazarian & 
Reese, 2015; P. P. Reese, Boudville, & Garg, 2015; Ross, 2015). The data also are clear 
in demonstrating that when LKD renal function declines, it occurs more than 5 to 7 years 
after the nephrectomy (Muzaale et al., 2014).  
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Practice and Policy Considerations 
 It has been an ongoing challenge in the United States to enact policies requiring a 
comprehensive long-term assessment of living donor health. After two years, follow-up 
reporting is no longer required by OPTN/UNOS (OPTN, 2013) and the living donor is 
left to primary care for lifetime follow-up care. With only a short-term assessment 
required post-donation, living donors may go years without any preventive and primary 
health care services. The intent of a longer UNOS/OPTN living donor follow-up policy, 
including regular and routine monitoring including laboratory testing which could be 
established, the progression of renal function decay could be delayed or stopped. While it 
is recognized that the current OPTN/UNOS living donor follow-up policies were created 
and implemented with much comprise from the transplant community, health policy that 
dictates long-term follow-up for the donors would be advantageous. A policy that 
required longer than two-year follow-up would allow for a more timely recognition of the 
living donors at greater risk of developing post-donation renal failure.  Furthermore, a 
long-term living donor follow-up policy would allow the collection of the biological and 
medical data of all donors beyond two years. This would help to better predict long-term 
outcomes post-donation and would support selection of living donor candidates with the 
best-predicted outcome.  
As short-term (24-month) follow-up is difficult to achieve at the transplant center 
level and the complexity of long-term data collection (outside of established HIE as 
discussed in this dissertation) has been documented from the transplant center perspective 
(Amy D Waterman et al., 2013). Commonly, patient-level barriers are reported, noting 
that the donor is unable to return to the transplant center, that the contact information is 
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outdated, or that the donor does not want to be contacted. Most importantly and from a 
patient-centered perspective, there is currently a lack of reimbursement to the donor’s 
costs associated with follow-up. We know that indirect and direct post expenses vary 
increasingly by distance traveled to the transplant center (J. Rodrigue et al., 2016). Health 
system–level barriers such as the lack of reimbursement to programs to cover the cost of 
living donor follow-up, additional medical and laboratory testing, and staff time were 
also reported by OPTN member transplant programs surveyed (A. D. Waterman et al., 
2013).  
Improvements in follow-up may occur if transplant programs work with donors to 
develop plans to achieve follow-up, if programmatic standards are set for completeness in 
follow-up data reporting, and if sufficient staff resources are available to ensure ongoing 
post-donation contact. This acknowledges that the responsibility for lack of follow-up 
cannot be borne only by the transplant system. The patients themselves need incentives to 
continue to follow-up, either with the transplant center or with their primary care provider 
(PCP). Transplant centers, OPTN/UNOS policy, and current practice recommendations 
support the idea of living donor follow-up in primary care settings (Leichtman et al., 
2011). With the documented barriers of follow-up from the transplant center perspective 
(Amy D Waterman et al., 2013), primary care is an ideal care environment for the 
management of corrective and preventive clinical measures, including lifestyle 
modifications that could mitigate the progression of chronic disease leading to renal 
decline.  
Placing LKD follow-up within the context of primary care eliminates potential 
conflicts of interest with transplant providers. The LKD normally has no connection with 
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the transplant physicians aside from the surgery, and there is evidence showing that 
transplant physicians are more likely to report that living donor health is good, making 
the argument that follow-up is not needed (D. A. Mandelbrot & Pavlakis, 2012). 
Theoretically, PCPs can conduct all aspects of the annual follow-up and then deliver the 
results to OPTN/UNOS, where the LKD is already known via living donor registration 
and follow-up forms. The detection of declining renal function through laboratory tests 
such as serum creatinine and urine protein screening tests should prompt referral to a 
nephrologist. Currently there is no formal education directed towards PCPs that provide 
clinical practice recommendations for the post-donation care and lifetime management of 
LKDs. This educational guidance could be a new project considered by the OPTN/UNOS 
Living Donor Committee in the future.   
The Henderson Conceptual Framework for Living Kidney Donor Follow-Up 
supports the theory that structures and processes of care impact outcomes of care. 
Proposals to improve and to enhance the quality of LKD follow-up must acknowledge 
the two structural elements of care including the U.S. organ transplant system and the 
individual transplant center that is responsible for the timely and complete reporting. 
There are both internal and external processes of LKD follow-up care, including care 
provided at the individual transplant center and care that is expected long-term in primary 
care settings. Outcomes of these care processes result in both short-term and long-term 
collection of clinical data on living donor health and wellbeing.  
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Future Research 
Formal Validation of Text-Mining Algorithm  
This dissertation advances towards our understanding of HIE as a new source for 
evaluating health outcomes in LKDs. In addition, the protocol for the identification of 
LKDs within the HIE presents a new approach to capturing and extracting data in 
transplantation research. As a preliminary step to this study, I will have the ability to 
formally validate the text-mining terms used to identify LKDs for the Indiana University 
Health cohort (See Chapter 3 for a brief description of the methodology) in the Johns 
Hopkins comprehensive Electronic Medical Record (EMR) system that contains records 
of all past LKDs who donated at the center.  
Future Research on Indiana University Health Cohort  
 Future research on the cohort LKDs from Indiana University Health includes the 
study of longitudinal clinical health outcomes beyond the short-term follow-up period. In 
addition, future studies will include: an examination of post-donation hospitalizations; 
incidence of DM and HTN in the long-term follow-up period, diabetes control based on a 
glycosylated hemoglobin (HbA1C), anti-diabetic and anti-hypertensive medication use in 
those LKDs; and; LKD renal function (eGFR) trajectory based on pre-donation renal 
function data.  
A Text-Mining Approach to Understanding Sequelae of Live Donation  
Dorry Segev, MD, PhD, Professor of Surgery and Associate Vice Chair for 
Research, Department of Surgery, Johns Hopkins School of Medicine, has applied for a 
supplemental research award to the National Institute for Diabetes, Digestive, and Kidney 
Diseases (NIDDK) to provide me with protected time, training, and mentoring related to 
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conducting research focused on understanding live kidney donor risk. My goal is to 
become an independent investigator committed to improving clinical outcomes and 
quality of life for live kidney donors. My research proposal to the NIDDK aims to better 
understand the long-term sequelae of living kidney donation for LKDs, such as risk of 
developing post-donation conditions through a text-mining approach of medical records. 
Beyond structured data fields traditionally found in EMRs, unstructured clinically useful 
information can be found in plain text clinical and narrative notes (Raghupathi & 
Raghupathi, 2014). However, this information must often be manually ascertained and 
extracted from an EMR, which is a time-consuming and expensive process.  
Understanding Diabetes and Living Donation 
One example of information that is time-consuming to collect from an EMR is 
fasting blood glucose (FBG); structured data may contain laboratory values for serum 
glucose, but whether the sample was taken after fasting is unknown. Iterative text mining 
approaches and machine learning algorithms such as natural language processing (NLP) 
and have been used to identify procedures and to derive comorbidities and results from 
plain text reports in other clinical settings (Carrell et al., 2014; Martinell, Stålhammar, & 
Hallqvist, 2012; Salmasian, Freedberg, & Friedman, 2013; Wieneke et al., 2015) and to 
quantify association between diseases, conditions, and symptoms (Bassøe, 1995; Lee, 
Wu, & Yang, 2007; Meystre, Savova, Kipper-Schuler, & Hurdle, 2008; Roque et al., 
2011; Xiaoyan Wang & Amy Chused, 2008). 
As part of the OPTN requirements for screening and evaluation of living kidney 
donor candidates, FBG is required; donor candidates undergo either a glucose tolerance 
test or (in the presence of high perceived risk for diabetes, such as family history) a 
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HbA1C test (OPTN, 2016c). At some centers, HbA1C is tested in all donor candidates, 
regardless of metabolic risk. Diabetes mellitus (DM), in addition to uncontrollable 
hypertension or history of hypertension with evidence of end organ damage, is currently 
an OPTN exclusion criterion for living kidney donation (OPTN, 2016c). However, there 
was previously more variation in this practice among U.S. transplant centers as older data 
demonstrated that factors associated with DM in kidney donors are similar to those in the 
general population and that donors screened carefully at the time of donation do not 
appear to have disease acceleration (H. Ibrahim et al., 2010; P. Reese et al., 2008). 
Furthermore, historically protocols used by transplant centers to screen and exclude LKD 
candidates have not reduced the risk for post-donation diabetes (Boyarsky BJ, 2012; H. 
N. Ibrahim et al., 2009; Lentine et al., 2010). While a pre-donation FBG laboratory test is 
required by policy, this characteristic is difficult to extract automatically as recorded in 
donor medical records.  
An understanding of pre-donation FBG and incidence of post-donation diabetes 
mellitus (DM) may improve our knowledge about the long-term risks and sequelae 
associated with kidney donation, particularly for younger African-American (AA) donors 
who may be at higher risk (Steiner et al., 2014). This can improve donor selection 
processes, informed consent, and post-donation care. To better understand risk for the 
development of sequelae such as DM in LKDs, we propose an ancillary study within an 
on-going, R01-funded multicenter cohort of live donors. The parent R01 study is 
recruiting 4,215 AA live donors at 13 centers using a retrospective design to maximize 
the duration of long-term follow-up in each participant (since prospective study of donors 
requires 10-20 years before outcomes are manifest). The parent study conducts patient 
109	
	
	
	
interviews and collects longitudinal medical records including the comprehensive pre-
donation medical evaluation and all subsequent physician visits during the post-donation 
period.  
The proposed ancillary study leverages prior experience in applying a text mining 
approach and NLP in the medical setting with an existing multicenter study of LKDs. We 
propose to develop a novel case-detection algorithm for automatically ascertaining and 
extracting pre-donation FBG from EMRs of LKDs. We then propose to apply this novel 
case-detection algorithm to explore the association between pre-donation FBG and risk of 
post-donation DM. This concept is highly likely to generalize beyond FBG and DM. 
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APPENDICES 
Appendix A: Text-Mining Terms for a Natural Language Processing Case Finding 
Algorithm to Identify Living Kidney Donors in Chapter Three 
 
Any term in quotes is a search for that exact term; any term in quotes with a note after it 
“these words found within X words of each other” means that the terms in quotes must 
all be there, but they could appear in any order, and they can be up to “X” words away 
from each other.  
• "PRINCIPAL DIAGNOSIS: Living kidney donor" AND "donor nephrectomy"  
• "DISCHARGE DIAGNOSIS: Living kidney donor"  
• "DISCHARGE DIAGNOSIS: kidney donor"  
• "post donor nephrectomy" - these words found within 5 words of each other 
• "recent donor nephrectomy" - these words found within 5 words of each other  
• "procedure donor nephrectomy" - these words found within 7 words of each other 
• "discharge kidney donation" - these words found within 10 words of each other 
• "PRINCIPAL DIAGNOSIS kidney donor" - these words found within 10 words 
of each other  
o AND "procedure donor nephrectomy" - these words found within 10 
words of each other  
• "living donor nephrectomy" - these words found within 10 words of each other  
o AND NOT "kidney transplant" - these words found within 3 words of 
each other 
116	
	
	
	
o AND NOT "renal transplant" - these words found within 3 words of each 
other 
o AND  NOT "kidney transplantation" - these words found within 3 words 
of each other 
o AND  NOT allograft 
• "history donor nephrectomy" - these words found within 6 words of each other  
o AND NOT preoperative  
o AND NOT pre-op  
o AND NOT pre-op  
o AND NOT transplant  
o AND NOT transplantation 
• "history kidney donation" - these words found within 5 words of each other  
o AND NOT preoperative  
o AND NOT pre-op  
o AND NOT preop  
o AND NOT evaluate  
o AND NOT examination  
o AND NOT evaluation 
• "PRINCIPAL donor" - these words found within 5 words of each other 
o AND kidney OR nephrectomy OR renal 
o AND living  
o AND NOT "procedure transplant" - these words found within 7 words of 
each other 
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o AND NOT "procedures transplant" - these words found within 7 words of 
each other  
o AND NOT "principal transplant" - these words found within 7 words of 
each other  
o AND NOT "kidney transplantation" - these words found within 3 words of 
each other 
• “procedure performed kidney donation" - these words found within 10 words of 
each other 
• "ADMISSION DIAGNOSIS renal donor" - these words found within 3 words of 
each other 
• "DISCHARGE DIAGNOSIS renal donor" - these words found within 3 words of 
each other 
• "ADMISSION DIAGNOSIS: Donor nephrectomy" - these words found within 3 
words of each other 
• "DISCHARGE DIAGNOSIS: Donor nephrectomy" - these words found within 3 
words of each other 
• "ADMISSION DIAGNOSIS: kidney donor" - these words found within 3 words 
of each other 
• "DISCHARGE DIAGNOSIS: kidney donor" - these words found within 3 words 
of each other 
• "ADMITTING DIAGNOSIS: Renal donor" - these words found within 3 words 
of each other 
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• "PREOPERATIVE DIAGNOSIS: Kidney donor" - these words found within 3 
words of each other 
• "POSTOPERATIVE DIAGNOSIS: Kidney donor" - these words found within 3 
words of each other 
• "underwent donor nephrectomy" - these words found within 3 words of each other 
 
And excluded reports with these terms, which were found in reports for kidney 
recipients: 
• "Living related donor renal allograft" 
• "Successful living related donor renal transplant" 
• "kidney rejection" 
• "transplant and nephrectomy of that" 
• "Renal transplant" 
• "History of kidney transplant" 
• "related renal transplant" 
• "post kidney transplantation” 
• “Autotransplant” 
• “Autotransplantation”  
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Appendix B: Sensitivity Analysis for the Donation Year Variable in Chapter Four 
Model # 1 SCr24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 1.115 .0496 
50-59 1.342 0.093 
60+ 2.979 0.002* 
Race   
(Non-black or African-American)   
Black or African-American 1.439 0.134 
Donor Era   
(1998-2003)   
2004-2014 
 23.972 0.000* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: SCr24= Serum Creatinine laboratory follow-up data at 24-months  
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds  
b. P-values significant at <0.05 are marked * 
 
Model # 2 SCr24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 1.193 0.284 
50-59 1.456 0.038* 
60+ 2.862 0.004* 
Race   
(Non-black or African-American)   
Black or African-American 1.503 0.106 
Donor Era   
(1998-2004)   
2005-2014 
 0.041 0.000* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: SCr24= Serum Creatinine laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds  
b. P-values significant at <0.05 are marked * 
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Model #3 SCr24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 1.275 0.170 
50-59 1.596 0.016* 
60+ 2.609 0.015* 
Race   
(Non-black or African-American)   
Black or African-American 1.960 0.013* 
Donor Era   
(1998-2003)   
2004-2008 
 8.535 0.000* 
2009-2014 
 55.949 0.000* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: SCr24= Serum Creatinine laboratory follow-up data at 24-months 
N = 1,212 
SCr24= Serum Creatinine laboratory follow-up data at 24-months 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
Model #4 SCr24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 1.309 0.131 
50-59 1.655 0.010* 
60+ 2.572 0.017* 
Race   
(Non-black or African-American)   
Black or African-American 1.961 0.013* 
Donor Era   
(1998-2004)   
2005-2008 
 9.213 0.000* 
2009-2014 
 49.250 0.000* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: SCr24= Serum Creatinine laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
 
Note: Model #5 SCr24 was selected for analysis and presentation in the manuscript  
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Model #6 SCr24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 1.306 0.139 
50-59 1.726 0.006* 
60+ 3.012 0.006* 
Race   
(Non-black or African-American)   
Black or African-American 1.973 0.013* 
Donor Era   
(1998-2003)   
2004-2008 
 8.508  
2009-2012 
 73.705 0.000* 
2013-2014 25.174 0.000* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: SCr24= Serum Creatinine laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
 
Model # 7 UA24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 0.504 0.118 
50-59 0.743 0.500 
60+ 0.608 0.632 
Race   
(Non-black or African-American)   
Black or African-American 2.080 0.115 
Donor Era   
(1998-2003)   
2004-2014 
 2.293 0.088 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: UA24= urinalysis laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds  
b. P-values significant at <0.05 are marked * 
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Model # 8 UA24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 0.515 0.129 
50-59 0.756 0.526 
60+ 0.589 0.610 
Race   
(Non-black or African-American)   
Black or African-American 2.101 0.110 
Donor Era   
(1998-2004)   
2005-2014 
 2.578 0.35 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: UA24= urinalysis laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
 
 
Model #9 UA24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 0.514 0.128 
50-59 0.765 0.543 
60+ 0.543 0.557 
Race   
(Non-black or African-American)   
Black or African-American 2.293 0.076 
Donor Era   
(1998-2003)   
2004-2008 
 1.467 0.484 
2009-2014 
 3.117 0.023* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: UA24= urinalysis laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
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Model #10 UA24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 0.518 0.134 
50-59 0.768 0.549 
60+ 0.540 0.554 
Race   
(Non-black or African-American)   
Black or African-American 2.278 0.078 
Donor Era   
(1998-2004)   
2005-2008 
 1.716 0.304 
2009-2014 
 3.293 0.011* 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: UA24= urinalysis laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
 
Note: Model # 11 of UA24 was selected for analysis and presentation in the manuscript 
Model #12 UA24   
Variable  Odds Ratioa (OR) 
 
P- valueb 
Age   
(19-39)   
40-49 0.515 0.130 
50-59 0.811 0.637 
60+ 0.600 0.625 
Race   
(Non-black or African-American)   
Black or African-American 2.291 0.077 
Donor Era   
(1998-2003)   
2004-2008 
 1.462 0.489 
2009-2012 
 3.747 0.009* 
2013-2014 1.104 0.907 
Source: 1998-2014 Indiana Network for Patient Care 
Notes: UA24= urinalysis laboratory follow-up data at 24-months 
N = 1,212 
a. Odds ratio = elog-odds = eβ. Also known as relative odds 
b. P-values significant at <0.05 are marked * 
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Appendix C: Organ Procurement and Transplantation Network/United Network  
for Organ Sharing Living Donor Follow-Up Form Images 
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Appendix D: Literature Review of Studies of Living Donor Outcomes 
Adapted from the Kidney Disease Improving Global Outcomes Evidence Review for the 
Development of Clinical Guidelines Michelle Brasure, PhD, MSPH, MLIS, Yelena 
Slinin, MD, MS, Maureen Carlyle, MPH, Areef Ishani, MD, MS, Keith Eidman, DO, 
Jason Bydash, DO, Saugar Maripuri, MD, MPH and Timothy J. Wilt, MD, MPH of the 
Minnesota Evidence Review Team: The Minneapolis VA Healthcare System and the 
Center for Chronic Disease Outcomes Research, the University of Minnesota Schools of 
Medicine and Public Health and Hennepin County Medical Center 
 
Living Kidney Donor Outcomes by Donor Age 
Renal function 
Ten studies reported renal function by age. In the three that looked at those with GFR 
<60 mL/min1.73m2, all found older donors at greater risk (Dols et al., 2011; H. N. 
Ibrahim et al., 2009; J. H. Lee et al., 2007).  Age at donation was significantly associated 
with greater odds of CKD (defined as eGFR <60 ml/min/1.73m2) in three studies (H. N. 
Ibrahim et al., 2009; J. H. Lee et al., 2007; Lentine & Patel, 2012) and not associated in 
one study (Tsai et al., 2013). Greater donor age was correlated with lower GFR at follow-
up in two studies in Swedish living donors (Fehrman-Ekholm et al., 2011; von Zur-
Mühlen, Berglund, Yamamoto, & Wadström, 2014). Frequency of eGFR < 60 ml/min 
was greater among donors who were 60 years or older at the time of donation compared 
to donors who were younger than 60 years of age (80% vs 31%) (Dols et al., 2011).  
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Older age at donation was associated with increased risk of CKD diagnoses as 
determined by administrative billing claims over an average 7.7 years follow-up (4% 
increase per year) (Lentine et al., 2010). Mean eGFR was 71ml/min/1.73m2 among 
donors older than 60 at the time of donation compared to 78.5ml/min in younger donors 
after 6.7 years of follow-up (Gracida, Espinoza, Cedillo, & Cancino, 2003).   
One study did not find any difference in eGFR, frequency of eGFR <60 ml/min1.73m2, 
as well as eGFR < 45 ml/min/1.73m2 among donors who donated before they turned 18 
compared to donors who donated between the ages of 18 and 30 (MacDonald et al., 
2014).  
 
The one study that looked at serum creatinine found no difference at follow-up for those 
aged 21-35 and 36-50, but found a difference in those 51-69 (mean creatinine of 1.0 
versus 0.8 mg/dL) (El-Agroudy et al., 2007). The quality of evidence for the outcome 
was deemed very low by KDIGO.  
 
Hypertension  
Hypertension in LKDs was reported in six studies defined by either blood pressure or 
treatment by medication included in the KDIGO systematic review for the development 
of clinical practice guidelines. Dols et al. reported risk of HTN in older donors (>60 years 
old) comparable to that in younger donors (10% versus 6%, p=0.56) (Dols et al., 2011).   
In one study older age at follow-up was associated with 5 mmHg higher systolic blood 
pressure (Fehrman-Ekholm et al., 2011).  Two studies reported that older age at donation 
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was associated with greater risk of drug treated hypertension (H. N. Ibrahim et al., 2009) 
(Lentine et al., 2014).  
 
El-Agroudy et al. looked at hypertension medications in donors ages 21-35, 36-50 and 
51-69 and reported a greater number of older donors using one or two medication than 
younger donors at 10.7 years of follow-up (12.6%, 32.5% and 31.8%) (El-Agroudy et al., 
2007).  
 
Diabetes  
One study reported that older age at donation was associated with a 5% higher risk of 
drug-treated diabetes over an average 7.7 years of follow-up (Lentine et al., 2010) 
Lentine The quality of evidence for the outcome was deemed as low by KDIGO.  
 
Living Donor Outcomes By Donor by Sex 
Seventeen studies analyzed donor outcomes by sex. The studies reported mean / median 
lengths of follow-up ranging from 5.4 to 12.2 years which is longer than the 24-month 
follow-up as presented in the present study. Quality of evidence was deemed to be low to 
very low for all of the outcomes by KDIGO. 
 
Renal function 
Six studies reported renal function by gender. Two studies reported no significant 
increase in risk of post-donation eGFR <60 ml/min by MDRD in women compared to 
men (J. H. Lee et al., 2007; Tsai et al., 2013). One study reported greater odds of GFR < 
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60 ml/min/1.73m2 in women compared with men (OR: 3.11; 95% CI:1.11 to 8.67) (H. N. 
Ibrahim et al., 2009). One study reported greater risk of claims for CKD in male donors 
compared to female donors (AHR: 1.64; 95% CI: 1.16 to 2.34) (K. L. Lentine et al.).  
 
One study reported similar GFR in male (81.6) and female (79.4) donors at 10 year of 
follow-up, p-value was not (Karakayali, Moray, Demirag, Yildirim, & Bilgin, 1998) 
while another study reported higher MDRD eGFR in males (69+13 ml/min/1.73m2) than 
females (65+12 ml/min/m2), p<0.01.(von Zur-Muhlen et al.) The quality of evidence for 
the outcome was very low.  
 
Hypertension 
Three studies reported HTN by gender (El-Agroudy et al.; K. L. Lentine et al., 2010; Tsai 
et al., 2013). In one study incidence of HTN was not different between male and female 
donors at 5.5 years (Tsai et al.). In another study HTN (>140/90 mmHg) was more 
common among female donors (24.7 versus 17.8%, p=0.03) (El-Agroudy et al., 2007). A 
third study revealed a greater risk of drug-treated HTN among male donors (AHR: 1.21; 
95% CI: 1.03 to 1.43) (K. L. Lentine et al.). The quality of evidence for the outcome was 
very low.  
 
Diabetes 
One study reported diabetes diagnosis by gender (K. L. Lentine et al.). There was no 
significant difference in risk of diabetes by claims diagnosis or drug-treated diabetes 
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between male and female donors (K. L. Lentine et al.). The quality of evidence for the 
outcome was very low.  
 
Living Donor Outcomes By Race 
Renal function 
One study compared eGFR in African American donors compared to African American 
non-donors. The average serum creatinine was 1.2 +0.3 mg/dL and the average eGFR 77 
+19 mL/min/1.73 m2 in donors and 0.9 +0.2 mg/dL and 109 +17 mL/min/1.73 m2, in non-
donors, respectively at an average follow-up of 6.8 years. The number (proportion) of 
donors with an eGFR < 60 and < 45 mL/min/1.73 m2 was 16 (15.5%) and 6 (6%), 
respectively, in donors while none of the non-donors had an eGFR<60 mL/min/1.73 m2 
(Doshi et al., 2013). The quality of evidence for the outcome was low.  
 
Hypertension 
One study compared risk of hypertension defined as BP> 140/90 mmHg or use of blood 
pressure medications among African American donors and African American healthy 
non- donors. After a mean follow-up of 6.8 years, African American donors had greater 
risk of hypertension compared to African American non-donors (40.8%vs 17.9%, 
absolute difference of 22.9%, [RR: 2.3; 95% CI: 1.6 to 3.4])(Doshi et al., 2013). The 
quality of evidence for the outcome was very low.  
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Diabetes 
One study compared risk of diabetes among African American donors and African 
American healthy non-donors. After a mean follow-up of 6.8 years, African American 
donors had a frequency of diabetes similar to that of African American non-donors (1.9% 
vs 1.7%, absolute risk difference of 0.2%, [RR: 1.14; 95% CI: 0.21 to 6.13]) (Doshi et al., 
2013) The quality of evidence for the outcome was very low.  
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2010 
Critical Care Extender Intern, David Geffen School of Medicine at UCLA, 
2004 
Assistant to the Director, Student Health Services, Pepperdine University, 2003 
Neonatal Intensive Care Unit Volunteer, IU Health, Riley Hospital for 
Children, 2003 
 
MEDIA, ENTERTAINMENT AND DIGITAL PRODUCTION 
EXPERIENCE 
2015 WXIN (FOX, 
Indianapolis) 
Guest Executive Producer with Nicole Pence 
#GotHeart Campaign Raises Organ Donor 
Awareness 
2015 WTHR (NBC 
Indianapolis) 
Guest Executive Producer with Naomi 
Pescovitz 
Carmel Couple Celebrates Gift of Life this 
Valentine’s Day 
 
	
	
	
	
2015 WOOD TV8 
(NBC West 
Michigan) 
Consulting Producer with Marc Thompson 
National Organ Donor Day 
2015 KDVR Fox 31 
(Denver) 
Production Shadow with Emmy award 
winning Colorado Everyday 
2011 National Kidney 
Foundation 
60th Anniversary Calendar 
February: To Give Love 
2009 WOOD TV 8 
(Grand Rapids, 
Michigan) 
News Research  
2008 – 
2011 
“Macey Leigh 
LLC” 
CEO and Creator 
2007 – 
2008 
“Playing for 
Keeps EPSN950 
Associate Producer 
2004 – 
2006 
Pathway 
Productions, LLC 
Digital Production Intern 
2001 – 
2003 
Visionary 
Productions/Grand 
Slam 
Production Associate  
1999 – 
2001 
Hendu 
Entertainment 
Production Assistant  
	
